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Abstract 
Drug-containing polymer nanoparticles are submicron-sized particles consisting 
of drug and stabilising or functional polymer. In this experimental study, 
methacrylic polymer nanoparticles with and without incorporated model drug 
were prepared using a novel method, namely, aerosol flow reactor method. This 
method involves first preparing a solution containing the drug and the polymer, 
followed by spraying the solution as nanosized droplets into a carrier gas stream, 
then drying the nanoparticles in a tubular laminar flow reactor tube, and finally 
collecting the nanoparticles. Model polymers used in this study were Eudragit L, 
Eudragit E, and Eudragit RS, which are commonly used methacrylic polymers in 
the pharmaceutical industry. Model drugs studied were beclomethasone 
dipropionate, ketoprofen, and naproxen. 
Various properties of the prepared nanoparticles were studied, such as particle 
size and size distribution, morphology, crystallinity, thermal properties, drug 
content, and drug release. It was found that this method could be used to produce 
amorphous, spherical, homogeneous matrix-type drug-polymer nanoparticles. 
The size of the particles was adjusted between 90 and 200 nm by the 
concentration of the solution. The morphology of the particles varied as a 
function of the properties and composition of the starting solution.  
The nanoparticles were collected as dry powders, but the stability of the powders 
in an amorphous form was found to be dependent on the interactions between 
the drug and the polymer. When the amount of the drug in the nanoparticles was 
below the solubility limit of the drug in the polymer, the amorphous 
nanoparticles were found to be stable and no crystallisation of the drug took 
place. When the amount of the drug was larger than the solubility limit, large 
crystalline structures were formed due to crystallisation of the drug. The 
crystallisation was also dependent on the thermal properties of the drug, as 
amorphous nanoparticles consisting of a drug having a high glass transition 
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temperature could be collected at room temperature. A low glass transition 
temperature of the drug led to crystallisation of the drug at ambient conditions, 
when the drug amount in the nanoparticles was larger than the solubility limit. 
Drug release from the nanoparticles could be modified by using polymers having 
specific solubility properties. 
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1. Introduction 
Drug nanoparticles can be specified as drug-containing particles having size 
smaller than 1 µm. Several applications have been proposed for these discrete 
submicron-sized particles, such as targeted drug delivery, controlled release, and 
increase in bioavailability of poorly water soluble drugs [14]. Due to the small 
size of the nanoparticles, drug targeting into, for example, cancerous tumours 
has been shown to be possible [5]. Moreover, nanoparticles can prove to be 
effective in stabilising and shielding labile drug molecules, such as proteins, 
peptides, or DNA molecules from degradation [24, 6, 7], thus opening new 
possibilities for protein drug delivery and gene therapy.  
Drug nanoparticles consist of the drug material and, usually, a stabilising 
polymer. In addition to physically stabilising the drug nanoparticles, the 
polymers can also act as functional agents, leading to sustained release of the 
drug or drug release triggered by changes in environmental conditions, for 
example in pH level. A variety of materials have been used for the preparation of 
drug nanoparticles, such as biodegradable polymers and non-biodegradable, but 
pharmaceutically acceptable polymers. Polymers of the latter type were used as 
model materials for the purposes of this thesis.  
First polymer nanoparticles for pharmaceutical applications were prepared in the 
late 1960s and early 1970s and were based on acrylamide micelle 
polymerisation [810]. Since then, various polymerization methods as well as 
methods involving the use of preformed polymers have been developed and 
studied [1, 9, 11]. Commonly, these methods result in a nanoparticle suspension 
in water stabilised with surfactants. However, the physical and chemical stability 
of such suspensions is often not adequate for practical applications. Some of the 
problems related to the instability, in addition to facilitating further processing, 
might be solved by having the nanoparticles as a dry powder [1215]. This 
research was aimed to study the possibilities to use a new method for the 
preparation of drug-containing polymer nanoparticles. In this novel method, 
namely, aerosol flow reactor method, the particles are formed by the evaporation 
of the solvent from nanosized droplets containing the drug and the polymer. The 
nanoparticles are collected directly as dry powder. As several of the previous 
preparation methods are dependent on the formation of an oil-in-water emulsion, 
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the partitioning of the drug between the immiscible phases of the emulsion 
affects the drug loading in the particles. In the aerosol flow reactor method, each 
of the droplets forms one particle during solvent evaporation and, therefore, drug 
leakage cannot take place. The amount of drug in the starting solution 
determines the drug content of the resulting particles.  
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2. Review 
2.1 Structures of drug nanoparticles 
Drug nanoparticles can be defined as solid particles having particle size between 
10 and 1000 nm. Drug nanoparticles consist of the drug and, optionally, of a 
biocompatible polymer, either biodegradable or non-biodegradable [9, 11, 16]. 
Nanoparticles can be further classified into nanocapsules and nanospheres based 
on their structure [1, 9, 11, 1719]. A nanocapsule particle consists of an oily 
core containing the lipophilic drug surrounded by a shell composed of the 
polymer. A nanosphere, however, has a matrix consisting of a homogeneous 
distribution of the drug and the polymer. The drug is either solubilised in the 
polymer matrix to form an amorphous particle or embedded in the polymer 
matrix as crystallites. Schematics of some exemplary structures of drug-
containing polymer nanoparticles are shown in Figure 1.  
 
Figure 1. Schematics of exemplary types of drug nanoparticles. A. A matrix-type 
nanoparticle, where the drug molecules are evenly dispersed in the polymer 
matrix. B. A core-shell nanoparticle, where a core containing the drug is 
covered with a polymer shell. C. A matrix-type nanoparticle, where drug 
crystals are imbedded in a polymer matrix. Adapted from [20]. 
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2.2 Applications of drug nanoparticles 
Both biodegradable nanoparticles for systemic drug delivery and non-
biodegradable nanoparticles for drug dissolution modification have been studied 
[3, 11, 21, 22]. Proposed applications for drug nanoparticles vary from drug 
targeting and delivery [3, 5, 11, 2326] to even gene [4, 7, 27] and protein [28, 
29] therapies. Administration of nanoparticles by, for example, parenteral [21], 
ocular [3032], transdermal [33], and oral routes have been studied. 
Nonetheless, the oral route is still the most convenient, preferred, and in many 
cases, also the most cost-effective method of drug administration [18, 28, 34
37]. Some of the proposed applications and administration routes of 
nanoparticles are summarised in Table 1.  
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2.2.1 Biodegradable and non-biodegradable materials 
The route of administration determines to some extent whether biodegradable or 
non-biodegradable materials can be used in the nanoparticles. For parenteral 
administration the particles need to be biodegradable [22, 38] to avoid the risk of 
polymer accumulation in the body and to ensure complete elimination. 
Intravenously administered drug-containing nanoparticles can be used to target 
drugs or even DNA [4, 6, 7, 27] into specific organs or sites, for example into 
cancerous tumours [5, 18, 23, 26]. Targeting the drug in a specific site of action 
increases the effectiveness of the drug while reducing side effects [3]. Due to 
their small size, nanoparticles can be taken up by cells, for example by 
endocytosis [4, 5]. Inside the cell, the pH levels of different compartments vary, 
so pH-dependent particles could be used to target drugs in specific organelles of 
the cell [4, 23, 39]. Biodegradable nanoparticles can also be used intravenously 
for sustained and constant systemic drug release [1, 24]. For this application, the 
surface of the particles has to be suitably modified to avoid the uptake by 
mononuclear phagocyte system [18, 40, 41]. Such nanoparticles, after injection, 
circulate in the body acting as drug reservoirs [41], and slow release of the drug 
from the nanoparticles leads to constant drug levels.  
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Table 1. Examples of applications and preparation methods of nanoparticles. 
 a) Range of mean particle sizes reported in the publication, expressed as 
mean±standard deviation of the distribution, where available. Geometric 
standard deviation used for lognormal distributions is described in [42]. 
Application Proposed 
administration 
route 
Materials Preparation method Mean particle sizes 
reported (nm) a 
Reference 
Bioavailability 
increase 
Oral Avarol + PBCA Emulsion 
polymerisation 
136±5707±98 [43] 
Bioavailability 
increase 
Oral RR01 + Eudragit L Emulsification-
diffusion 
292±22297±6 [34] 
Bioavailability 
increase 
Oral CGP 70726 + Eudragit 
L 
Emulsification-
diffusion 
275±5296±6 [44] 
Bioavailability 
increase 
Oral CGP 57813 + Eudragit 
L / Eudragit S 
Salting-out 245264 [45] 
Bioavailability 
increase 
Oral Danazol Wet milling 169 [46] 
Bioavailability 
increase 
Oral HO-221 Wet milling 453±23 [47] 
Bioavailability 
increase 
Oral Buparvaquone High pressure 
homogenisation 
558663 [48] 
Bioavailability 
increase 
Oral Cyclosporine A Evaporative 
precipitation into 
aqueous solution 
131526 [49] 
Insulin 
administration 
Oral Insulin + PBCA Interfacial 
emulsion 
polymerisation 
136±90152±51 [29] 
Reduction of 
gastric irritation 
Oral Naproxen Wet milling 270 [50] 
Drug targeting Ocular Flurbiprofen + PCL Solvent 
displacement 
201284 [51] 
Drug targeting Ocular Flurbiprofen + Eudragit 
RS / Eudragit RL 
Quasi-emulsion 
solvent diffusion 
1496 [52] 
Gene delivery Pulmonary pDNA + PLGA-PEI Solvent 
displacement 
207±11231±12 [53] 
Sustained 
release  
Pulmonary Insulin + PBCA Emulsion 
polymerisation 
255 [54] 
Drug delivery Oral / nasal / 
pulmonary 
Nafarelin acetate  
+ PLGA 
Emulsion-phase 
separation 
500800 [55] 
Sustained 
release 
i.m. Savoxepine + PLA Salting-out 230680 [56] 
Dissolution 
enhancement 
i.v. Tarazepide High pressure 
homogenisation 
347517 [57] 
Drug targeting i.v. Dalargin / Kyotorphin  
+ PBCA 
Emulsion 
polymerisation 
195289 [58] 
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Drug targeting i.v. Indomethacin /  
5-fluorouracil + PLGA 
Spontaneous 
emulsification 
solvent diffusion 
338±67637±40 [59] 
Cancer therapy i.v. Piposulfan / Etoposide / 
Camptothecin / 
Paclitaxel 
Wet milling 202±31279±30 [60] 
Toxicity 
reduction 
i.v. Primaquine + PLA Solvent 
displacement  
153169 [61] 
Drug targeting No routes 
proposed 
Amoxicillin Supercritical 
antisolvent 
precipitation 
2501200 [62] 
Drug targeting No routes 
proposed 
Insulin Electrospray 88117 [63] 
Drug targeting No routes 
proposed 
Triamcinolone 
acetonide + PLA 
Emulsification-
evaporation 
476±410710±406 [64] 
Drug targeting No routes 
proposed 
Atovaquone + PCL / 
PLA / PLGA 
Solvent 
displacement 
228±16242±33 [65] 
Drug targeting No routes 
proposed 
Tamoxifen + PCL Solvent 
displacement 
200300 [23] 
Gene delivery No routes 
proposed 
pDNA + PLGA Double emulsion-
evaporation 
589±190640±64 [7] 
Sustained 
release 
No routes 
proposed 
Isradipine + PCL / PLA 
/ PLGA 
Solvent 
displacement 
110208 [66] 
Technical 
studies on 
preparation 
method 
Oral / ocular / 
topical 
Indomethacin + EC / 
CAB / PMMA / 
Eudragit RS / Eudragit 
RL 
Emulsification-
evaporation 
100125 [12] 
Technical 
studies on 
preparation 
method 
No routes 
proposed 
Chlorambucil + PLA / 
PLGA / PCL / Eudragit 
S 
Emulsification-
diffusion 
246591 [67] 
Technical 
studies on 
preparation 
method 
No routes 
proposed 
PLA Emulsification-
diffusion 
100450 [68] 
Technical 
studies on 
preparation 
method 
No routes 
proposed 
PAA / PMMA / PBCA / 
PECA / PMCA 
Polymerisation 51145 [16] 
Technical 
studies on 
preparation 
method 
No routes 
proposed 
PLA / Eudragit S / 
Eudragit E / ethyl 
cellulose 
Salting-out 1721117 [69] 
 
However, for oral administration, a wider range of materials is available. For 
oral administration, there is no requirement that the particles need to be 
biodegradable. Instead, in oral administration, the nanoparticles can be used to 
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modify drug release [25, 36, 44, 45, 70]. In addition, non-biodegradable 
nanoparticles can be used, for example, for ocular [30, 32, 52] drug delivery. 
2.2.2 Oral administration 
It has been predicted that in the future a growing number of new, potential drug 
molecules will have bioavailability problems related to poor water solubility of 
these molecules [37, 7175]. Following administration, poorly water soluble 
drugs tend to be eliminated from the gastrointestinal tract before being fully 
dissolved and absorbed into the blood circulation, which results in a slower onset 
of action or in problems in achieving the required therapeutic level [37, 46, 72]. 
Consequently, these drugs have to be given in large doses to be effective. The 
high dose administration is not only very expensive but it also reduces patient 
compliance due to issues such as bad taste, frequent administration, or side 
effects. Commonly, the rate-determining step for the rate and extent of 
bioavailability and drug absorption is the drug dissolution rate [76, 77]. Increase 
in the dissolution rate of a poorly water soluble compound can result in higher 
bioavailability [44, 72]. Various approaches have been studied to increase the 
solubility of such drugs. The techniques proposed for solubility increase include 
solubilisation of drug into micelles or liposomes [78, 79], complexation or 
coating with hydrophilic substances such as poly(ethylene glycols) or 
cyclodextrins [8082], solid dispersions [77, 83, 84], and using an amorphous 
modification of the drug [34, 85, 86]. One means to increase dissolution rate, 
bioavailability, and oral absorption of an active material is to increase its surface 
area available for dissolution by, for example, decreasing particle size [34, 36, 
4649, 8791]. Examples of nanoparticle systems studied for bioavailability 
increase are shown in Table 1. 
The bioavailability of the drug is affected, in addition to solubility and 
dissolution rate, also by intestinal permeability [92, 93]. These factors are taken 
into account in the biopharmaceutical classification system, BCS. In the BCS, 
the drug materials are classified into four different groups according to their 
solubility and permeability: Class I: high solubility  high permeability, Class II: 
low solubility  high permeability, Class III: high solubility  low permeability, 
and Class IV: low solubility  low permeability [9295]. For the BCS, a drug is 
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considered to be highly soluble when the highest dose is soluble in 250 ml water 
over the pH range of 1.07.5. Similarly, a drug is considered to be highly 
permeable when the intestinal absorption is over 90% of the orally administered 
dose [93, 96]. When the bioavailability of a drug substance is limited by its poor 
solubility, enhancing the dissolution can improve bioavailability. However, 
when the bioavailability is limited by the intestinal permeability, faster 
dissolution is not expected to increase bioavailability. Therefore, of the BCS 
classes, class II drug molecules are the most promising to show increase in 
bioavailability as a result of enhanced solubility. 
2.2.2.1 Effect of pH on the solubility of the drug 
The gastrointestinal tract consists of several parts having different conditions 
with respect to pH, and fluid and enzyme compositions [97]. The pH of stomach 
is acidic, ranging from 1.3 to 5 depending on the fed-fasted conditions [90, 97, 
98]. The small intestine, however, has a significantly higher pH level ranging 
from 6.5 to 7.5 [90, 98]. 
The environmental pH affects the dissolution of drug molecules, which contain 
ionisable groups [90]. Commonly, the neutral acid or basic form is insoluble or 
less soluble in water than the ionised form of the drug. The ionisation pH of the 
molecule can be described by the pKa value of the compound. This value 
characterises the pH at which half of the molecules carry a charge whereas half 
of the molecules are in neutral form. Weakly basic molecules are protonated in 
the acidic stomach, and are thus soluble to gastric fluid. In comparison, weakly 
acidic drugs containing e.g. carboxylic acid groups are poorly soluble in acidic 
conditions. When these compounds enter the region of higher pH, they are 
ionised and soluble. However, as several commonly used drug compounds have 
pKa values smaller than the pH of the absorption site, these compounds will be 
soluble early in the upper instestine [90] causing irritation and other side-effects.  
The drug release in the GI tract can be controlled using pH-sensitive materials, 
in which the drug is released specifically in the small intestine near the 
absorption site. pH-dependent materials, which are insoluble in the acidic 
environment of the stomach but dissolve in the intestinal fluid are called enteric 
materials [98, 99]. Such materials have been traditionally used to coat tablets 
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and capsules to allow the drug dosage form to pass intact in the acidic 
environment of the stomach. These coatings have been used to prevent the 
degradation of labile drugs caused by the acidic environment or gastric enzymes, 
to reduce irritiation of gastric mucosa, and to deliver drugs selectively to the site 
of absorption [98, 99]. Enteric coating materials are polymers, which contain 
acid groups. In the acidic environment of the stomach the acid groups are 
nonionised, and the coating material is insoluble. Rapid dissolution and drug 
release is achieved in the upper intestine as a function of pH change in the 
environment. The polymer acid groups are ionised at higher pH and the material 
dissolves [98]. 
Side effects such as irritation, mucosal damage, and ulceration are often 
encountered in conjunction with the administration of, for example, non-
steroidal anti-inflammatory drugs [50, 100102]. These side effects have been 
shown to be at least partly of local instead of systemic origin [50, 103]. The 
protection of the mucosa can be accomplished by encapsulation of the drug by a 
protective layer surrounding the drug molecules, thus avoiding direct contact of 
the drug with the mucosal tissue [13, 14, 104, 105]. To maximise absorption and 
to improve bioavailability, the drug should be released selectively close to the 
site of absorption [44]. For instance, by using pH-dependent encapsulation 
materials, the drug release can be triggered by the change in pH level of the 
environment [34, 45, 97].  
Oral administration of drugs incorporated in pH-sensitive particles has been 
shown to be effective for poorly water-soluble compounds in increasing drug 
bioavailability and giving fast absorption [34, 45, 70]. It has been speculated, 
that the good bioavailability of pH-controlled nanoparticulate drug systems 
relies in several properties, including the high specific surface area of the 
system, drug in an amorphous form or molecularly dispersed in the polymer 
matrix, and the release of drug close to the absorption site [34, 44, 70]. The 
dissolution of the particles should not be too rapid, however, as this might lead 
to drug precipitation [45] or crystallisation, [106] but should not be too slow 
resulting in elimination of the particles before absorption, either [45].  
Drug nanoparticles containing a protective material can also be used to shield 
labile drugs such as peptides and proteins against degradation in the biological 
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environment caused by either acidic conditions of the stomach or by 
gastrointestinal enzymes [1, 28, 29, 107, 108]. Commonly, peptides and proteins 
have to be administered by injection to avoid degradation, and repeated 
injections are required [108]. Oral administration of a protein has been shown to 
be possible by formulating the drug as by using suitable excipients, which are 
resistant to gastric enzymes [28, 29, 109]. 
2.3 Theory of dissolution 
The dissolution of a solid material can be described by a diffusion layer model. 
This model was first suggested by Bruner and Tolloczko [110] and further 
developed into its classical form by Nernst and Brunner [111, 112]. When a 
particle of a solid material is immersed in a solvent, a stagnant diffusion layer is 
formed around it (see Figure 2).  
 
Figure 2. Schematic representation of a model depicting the dissolution process 
[113]. 
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In this diffusion layer, the velocity of the medium can be taken as zero and the 
transport of the dissolved molecules from the surface of the particle into the bulk 
liquid takes place by the diffusion of the molecules through the diffusion layer. 
The thickness of the diffusion layer is dependent on the experimental conditions 
such as the stirring rate [112]. The diffusion layer model assumes that the 
dissolution is very rapid and that saturation is achieved at the particle surface. At 
the surface of the particles, the concentration of the dissolving material is the 
saturation concentration, Cs, and the concentration is linearly decreasing in the 
diffusion layer until it reaches the concentration of the bulk medium, C (see 
Figure 2). Therefore, the diffusion of the molecules through the stagnant 
diffusion layer is the rate-limiting step for dissolution. The driving force for the 
diffusion of the molecules is a negative concentration gradient, which is 
consistent with the Fick´s first law of diffusion:  
x
CDJ
∂
∂
−= , 
where J is the diffusion current, the amount of material that passes 
perpendicularly through a surface per unit time, D is the diffusion coefficient of 
the dissolving species, and ∂C/∂x is the linear concentration gradient [114].  
The chemical properties of the dissolving material affect the stagnant diffusion 
layer [115119]. Especially, for the weakly acidic molecules, the 
microenvironment of the diffusion layer can show pH levels different from the 
bulk medium. Weakly acidic molecules are poorly soluble in the nonionised 
state below their pKa. Above their pKa, the acid groups dissociate and the 
molecules are soluble. The molecules dissolve in the diffusion layer in the 
nonionised state, but deprotonation can then take place in the diffusion layer. 
Consequently, the pH of the microenvironment is lower than of the bulk 
solution, as the acidic molecules self-buffer the diffusion layer. The lower pH of 
the diffusion layer decreases the solubility of the solid acidic material. Such self-
buffering is relevant when the pH of the solution is higher than the pKa value of 
the dissolving material [115, 116].  
When the bulk solution consists of a buffer solution, the diffusion layer pH of a 
solid acidic material can be affected. The buffer solution is able to consume the 
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released hydrogen ions, and the surface pH of the dissolving material approaches 
that of the bulk, leading to an increase in the dissolution rate [116]. Increasing 
buffer pH, buffer ionic strength, or buffer basicity increase the pH of the 
diffusion layer [116], resulting in faster dissolution. A schematic representation 
of the concentration of various ionic species in as a function of distance from the 
surface of a particle consisting of a carboxylic acid in buffer solution is shown in 
Figure 3 [116]. 
 
Figure 3. Diagrammatic representation of a solid carboxylic acid, HA, 
dissolving into a reactive medium containing hydroxide ion and buffer 
components B and BH+ with a Nernst diffusion layer existing between the solid 
and the bulk solution. Sink conditions exist in the bulk solution, and the 
products, BH+, A-, and H+, diffuse out of the diffusion layer at a rate determined 
by their chemical reactivity and diffusivity [116].  
According to the Noyes-Whitney equation [112114, 120, 121], the dissolution 
of a material is dependent on surface area of the dissolving species:  
( )CC
h
DA
dt
dm
s −= , 
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where dm/dt is the dissolution rate, D is the diffusion coefficient, A is the surface 
area available for solvent, and h is the thickness of the diffusion layer (denoted 
as l in Figure 2). When Cs >> C, sink conditions prevail and the amount of 
material dissolved does not have any effect on its solubility or dissolution rate. 
Based on the Noyes-Whitney equation, the dissolution rate of a material can be 
increased by increasing the surface area available for the solvent. This can be 
achieved, for example, by reducing particle size [34, 36, 4649, 8791]. 
According to the Noyes-Whitney equation, increased dissolution rate can also be 
attained by increasing the saturation solubility Cs of the material. Saturation 
solubility can be increased, for example, by solubilisation of poorly water 
soluble drugs into micelles, liposomes, [78] or into cyclodextrins [8082].  
The solubility of a material can be expressed as a function of particle size by 
Gibbs-Thomson (also known as Ostwald-Freundlich or Kelvin equation).  
RTr
V
c
c SLr γ2ln =⎟⎟
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⎞
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⎝
⎛
∞
, 
where cr is the saturation solubility of a particle having a radius r, c∞ is the 
solubility of a particle of infinite radius, γSL is the surface free energy, V is the 
molar volume, R is the molar gas constant, and T is the temperature. On the 
basis of Gibbs-Thomson equation, the saturation solubility of a material depends 
on the compound itself (V), on the surface free energy (γSL), and on the particle 
size (r) [36, 114, 122]. According to the equation, the solubility of a material 
will increase exponentially as a function of reducing particle size [75], 
particularly when the particle size is below 1 µm [36, 71, 75, 122].  
It can be seen from the Gibbs-Thomson equation that also the surface free 
energy of the material affects on its solubility. The amorphous state of the 
material is theoretically the most energetic crystal state [123, 124], thus has the 
highest surface free energy, and should consequently have the highest solubility 
[36, 75, 124, 125]. Accordingly, the dissolution rate of the drug can also be 
increased by using an amorphous modification of the drug [37, 49, 85, 86, 124, 
126128]. 
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2.4 Amorphous drug materials and amorphous solid 
solutions consisting of drug and polymer 
Increase in the dissolution rate of a drug can be achieved by using an amorphous 
form of the drug [49, 85, 86, 124, 128]. Amorphous materials do not have any 
long-range order such as crystal lattice in comparison to crystalline materials 
[128]. Commonly, small drug molecules can easily crystallise, and consequently 
both the amorphous state and the crystalline state are possible. The amorphous 
state has higher internal energy, larger free volume, and greater molecular 
mobility in comparison to crystalline state [129]. These properties of the 
amorphous state lead to greater solubility, but as a drawback the amorphous 
structure is metastable with respect to crystalline state, and has a tendency to be 
spontaneously converted into a crystalline state of lower energy [128133]. The 
differences in the energies of the crystalline and the amorphous (glassy) state are 
shown schematically in Figure 4 for an exemplary molecule, which can exist 
both in an amorphous and in a crystalline state. The crystalline material shows a 
small increase in enthalpy and volume as a function of temperature 
corresponding to a constant heat capacity and thermal expansion coefficient 
[129]. At the melting temperature, Tm, a first-order phase transition is observed 
as a change in the slope of enthalpy and volume versus temperature. When the 
liquid is cooled rapidly, it is possible for the system to follow the equilibrium 
line to the supercooled liquid region instead of converting back to the crystalline 
state. At the glass transition temperature, Tg, the supercooled material forms a 
glassy nonequilibrium state having high energy [129]. The Kauzmann 
temperature, TK, represents the lower limit for glass transition temperature [129].  
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Figure 4. Schematic depiction of the variation of enthalpy (or volume) as a 
function of temperature for crystalline and amorphous (glassy) solid material 
[129]. 
In the case of crystallisable, small drug molecules, the physical stability of the 
amorphous structure is affected by the molecular mobility, which depends on 
humidity and temperature [123, 128, 129, 133, 134]. Amorphous structures are 
more prone to chemical solid-state reactions and water absorption, which can 
further promote chemical degradation and crystallisation [125, 128, 135139]. 
Crystallisation is also affected by molecular steric structure, symmetry, and 
hydrogen bonding tendency [140, 141].  
Due to the physical instability the amorphous drug materials tend to crystallise at 
common storage and use temperatures. Therefore, amorphous structures from 
small, crystallisable drug molecules are difficult to maintain at ambient 
conditions. In comparison to crystallisable drug materials, polymer materials, 
especially statistical copolymers, are mostly amorphous at ambient conditions 
[142, 143]. Incorporating drug molecules in a polymer can lead to the formation 
of an amorphous solid solution, in which the drug molecules are dissolved by the 
polymer. Such an amorphous solid solution can be formed when the drug 
molecules have a good solubility in the polymer [77, 84, 91, 144]. The 
interactions between the two types of molecules must be comparable to 
intramolecular interactions to avoid phase separation [145]. Interactions such as 
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electrostatic forces and hydrogen bonds can occur between the functional groups 
of the polymer and drug molecule [146156]. A small amount of drug in the 
polymer matrix can be soluble, whereas higher amounts of drug can exceed the 
solubility limit of the drug in the polymer, leading to the formation of separate 
crystals [157159].  
Amorphous solid solutions have been used to achieve faster dissolution rates of 
drugs [77, 144, 160] and to modify drug release [84]. The role of the polymeric 
component in the amorphous solid solution is to provide a means to solubilise 
drug materials in the amorphous matrix and, in some cases, to control the 
dissolution of the drug. When the glass transition temperature of the polymer is 
higher than the ambient temperature, the polymer is in a glassy state and the 
material is brittle and hard [143]. Considering the preparation of nanoparticles 
having an amorphous solid solution structure, when the polymer is in the glassy 
state, it also provides mechanical strength to the particles. Under these 
conditions, the mechanical hardness and integrity of the particles can be 
maintained and coalescence of the particles can be avoided. Consequently, the 
production, collection, and possible subsequent processing of the nanoparticles 
are facilitated [107]. 
2.5 Polymer materials of the study 
Model polymers were chosen for this study to investigate the preparation of 
drug-containing nanoparticles by the aerosol flow reactor method. The 
nanoparticles prepared in this study were aimed to be applicable to oral 
administration and, therefore, the polymers used had to be suitable for this 
application. Particularly, the requirements for the polymers were that they 
should be chemically stable with the drugs studied, non-toxic, accepted for oral 
administration, amorphous, and have glass transition temperatures higher than 
ambient temperature.  
The model polymers chosen for this study have been used in the pharmaceutical 
industry for various film-coating applications [8, 148, 161, 162]. These 
methacrylic copolymers, namely Eudragit L, Eudragit E, and Eudragit RS, are 
accepted for oral formulations. Eudragit L has commonly been used as an enteric 
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coating material, as it is not soluble in the acidic environment of the stomach. 
Above pH 6, it is rapidly dissolved, releasing the encapsulated material [161, 
162]. Eudragit E, however, is soluble at the acidic conditions due to its basic 
units. Therefore, it has been used as a rapidly dissolving coating, for example, to 
mask bad taste or bad smell of the encapsulated material, or to protect the 
material from moisture [161, 162]. Eudragit RS has been used as a sustained-
release coating material. Water can penetrate in the Eudragit RS material and 
dissolve the encapsulated material, which then diffuses in the aqueous phase and 
finally into bulk solution [161, 162]. Eudragit materials have also previously 
been used as excipients for drug-containing micro- and nanoparticles [52, 70, 
163167].  
The copolymers chosen are amorphous, and therefore, the formation of 
amorphous solid solutions with the drugs was assumed possible. The glass 
transition temperatures of the polymers studied are above ambient, and at room 
temperature the polymers are mechanically rigid and hard. Therefore, adequate 
mechanical hardness and rigidity of the nanoparticles was also expected. The 
polymers consist of different functional groups, which was presumed to lead to 
different interactions between the polymers and the model drugs. The polymers 
chosen are functional materials, which can be used for controlled release of 
drugs. Particularly, the three polymers chosen have different pH-dependent 
solubilities, which was assumed to affect on the drug release from the particles.  
2.6 Methods of preparation of drug nanoparticles 
Current methods used in the preparation of drug nanoparticles can be divided 
into two groups, namely, those based on polymerisation and those taking 
advantage of preformed polymers. Examples of nanoparticles produced using 
the various methods are listed in Table 1. In polymerisation methods, the 
monomers are polymerised to form the encapsulating polymer of the 
nanospheres or nanocapsules during the process [1, 10, 19, 20, 168, 169]. Small 
particle sizes, ranging from 50 to 300 nanometers have been achieved by 
emulsion polymerisation [16, 58]. Drug amount in the nanoparticles has been 
reported to vary from less than 1% (w/w) [43] to more than 10% (w/w), 
depending on the solubility of the drug [1, 10, 19, 20, 168, 169]. Drawbacks 
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which have limited the use of polymerisation methods for the synthesis of drug 
nanoparticles include the need to use surfactants to stabilise the emulsion during 
polymerisation, toxic or reactive residues of organic solvents, residues of 
initiators or unreacted monomers, risk of a chemical reaction between the drug 
molecule and the reactive monomer, and the formation of oligomers [1, 170, 
171]. The residues from the synthesis require extensive purification work to 
result in a pharmaceutically acceptable product [1, 11]. By using preformed 
polymers for the preparation of nanoparticles many of the problems involved in 
the polymerisation methods can be avoided [1].  
Probably the most common method to manufacture drug-containing polymer 
particles from preformed materials involves first dissolving the drug and the 
polymer into a water-immiscible solvent, such as dichloromethane or chloroform 
and forming a submicronic oil-in-water emulsion, for example by sonication. 
The organic solvent is evaporated using elevated temperature or reduced 
pressure [1, 11, 12, 40, 172, 173]. The resulting particle size and size distribution 
are determined by the emulsion droplet size and size distribution [172]. 
Generally, particle sizes from 100 to 800 nanometers have been reported [12, 34, 
44, 64]. Various modifications of the emulsification methods have been also 
described [7, 59, 67, 68, 174176]. Other examples of drug nanoparticle 
preparation methods include salting-out method [1, 56, 69], solvent 
displacement (nanoprecipitation or interfacial precipitation) method [1, 61, 170, 
177], phase separation method [55], evaporative precipitation into aqueous 
solution [49, 85], and electrospray technique [63]. Particle sizes from 100 to 300 
nanometers have been achieved with, for example, solvent displacement method 
[23, 51, 53, 61, 65, 66]. Reported drug loadings vary up to 50% (w/w) by 
emulsion method [12, 34, 44, 64] and up to 15% (w/w) by solvent displacement 
method [51]. The amount of the active ingredient entrapped in the nanoparticles 
manufactured by methods based on emulsification depends on the solubilities of 
the drug and the polymer. Drug partitioning between immiscible inner and outer 
phases of the emulsion reduces the amount of the drug that can be encapsulated 
in the nanoparticles [1, 12, 178181]. In addition, many of the synthetic 
polymers are soluble only in organic solvents, so chlorinated and/or toxic 
solvents must often be used, which increases the risk of pharmaceutically 
unacceptable solvent residues [67, 173, 178]. 
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Size-reduction techniques, such as wet milling and high-pressure 
homogenisation have also been used in attempts to create nanosized drug 
particles [46, 57, 60, 71, 72]. Long processing times are often required in order 
to reach submicron size, leading to an increased risk of microbiological 
contamination [36, 46, 60]. Moreover, the achievable particle size, shape, and 
morphology depend on the physicochemical properties of the drug, such as 
hardness and thermal stability [47, 48, 71, 75], and on the physicochemical 
properties of the stabiliser used [60] as well as on experimental parameters [36]. 
Particle sizes reported vary from less than 200 [46] to 700 nanometers [47, 48, 
50, 57, 60]. The size-reduction method is best suitable for poorly water soluble 
materials, as slightly water-soluble materials dissolve in water and show 
physical instability [72].  
Most of the current methods described above used to manufacture drug 
nanoparticles result in an aqueous suspension of nanoparticles [22]. Suspensions 
are, however, physically unstable and common problems of suspensions are drug 
leakage from the particles into water phase, drug degradation, microbiological 
problems, and physical changes, such as aggregate formation in the course of 
time [1, 14, 52, 182]. To prevent particle aggregation and coalescence, 
electrostatic and steric surfactants are included in suspensions [15, 22, 46, 57, 
71, 72, 172, 173]. To increase the physical and chemical stability of the 
nanoparticles, dry powders would be desirable [14, 15, 47, 171, 173]. Freeze-
drying (lyophilisation) and spray-drying of the aqueous suspensions to produce 
nanoparticle dry powders have been studied [14, 15, 182, 183]. However, these 
drying methods can induce physical changes in the nanoparticles during 
processing, such as aggregation or particle coalescence, or require the use of 
cryoprotectors to ensure particle stability during and after the process [1, 13, 47, 
171, 184].  
Drug-containing micro- and nanoparticles have also been prepared using 
supercritical fluids as either solvents or antisolvents for the drug and the polymer 
[178, 185194]. Commonly, such processes can lead to a solvent-free dry 
product, without the need for further drying steps while avoiding the use of 
surfactants. Nonetheless, the complex ternary system consisting of a 
supercritical fluid, a solvent, and solutes in the supercritical region can lead to 
the formation of multiple fluid and liquid phases, the prediction and control of 
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which is difficult [62, 195]. The particle size and the particle morphology are 
determined by the operating conditions [62, 178, 190]. The preparation of 
uniform multicomponent particles consisting of a drug and a polymer has been 
shown to be difficult due to different crystallisation and precipitation kinetics of 
the drug and the polymer molecules [190] and due to partitioning of the drug 
into supercritical fluid [178, 196]. Supercritical carbon dioxide, the most 
commonly used supercritical fluid, can swell some polymers and act as a 
plasticiser to the polymer, which leads to lowering of the glass transition 
temperature and to particle aggregation [178, 190, 195]. Moreover, these 
methods need special equipment able to withstand high pressures while 
simultaneously allowing accurate control of pressure and temperature.  
Spray-drying has been widely used for the production of micron-sized particles. 
Spray-drying involves the conversion of a solution droplet into a dry particle by 
evaporation of the solvent in a one-step process [126, 197, 198]. It has been 
shown that particles consisting of various polymers and drugs, both water-
soluble and water-insoluble, can be prepared without problems of drug leakage 
to another phase [165, 199, 200], and thus, the recovery of drug in the particles 
is almost quantitative [201]. Also temperature-labile compounds such as proteins 
and enzymes have been successfully spray-dried [126, 197, 202]. Most examples 
of spray-drying a mixture of a polymer and a drug have been shown to result in 
an amorphous product, where the drug is dispersed in the amorphous polymer 
matrix [126, 203, 204]. The particle properties, especially morphology, can be 
controlled by the solvent properties and the spray-drying variables [126, 164, 
200]. The structure of the particles can be further controlled by the choice of the 
starting solution system [197, 198, 205210].  
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3. Objective of the study 
The aim of this thesis was to develop an aerosol flow reactor system for the 
preparation of nanoparticles consisting of various polymers and drugs. Aerosol 
flow reactor method has previously been used for the manufacture of micron-
sized drug particles, and extending this approach to nanosized particles was 
studied. Polymer materials acceptable for oral administration of drugs were 
chosen for testing the suitability of this nanoparticle preparation method. The 
main purposes of this study were to specify the main factors affecting on the 
successful manufacture of the nanoparticles and to analyse the properties of the 
nanoparticles. 
The specific aims of the study were: 
o To evaluate the effects of various parameters, such as concentration of 
the starting solution (IV), solvent properties and solvent composition (II, 
III), and reactor temperature (I, III) on the nanoparticle size, size 
distribution, and morphology. The influences of drug and polymer on 
the formation of nanoparticles were studied (I, II, III). 
o To evaluate the physical properties, such as crystallinity, thermal 
properties, and drug release for the nanoparticles consisting of various 
combinations of methacrylic polymers and drugs ketoprofen (IV, V), 
naproxen (IV), or beclomethasone dipropionate (III).  
o To study the effects of the thermal properties of the drug and the 
interactions between the drug and the polymer on the collection of drug-
polymer nanoparticle dry powders (III, IV, V).  
Special interest was devoted to nanoparticles containing ketoprofen, as during 
the studies it was observed that these nanoparticles were amorphous with higher 
drug loadings than the nanoparticles containing naproxen (IV).  
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4. Experimental 
4.1 Aerosol flow reactor method for the preparation of 
nanoparticles 
The aerosol flow reactor method consists of three steps, i) atomisation of the 
solution containing the drug and the polymer to nanosized droplets, ii) drying the 
droplets in a heated tubular laminar flow reactor by solvent evaporation, and iii) 
collection of the solid particles. In this continuous particle preparation method, 
each of the generated droplets converts into one particle on drying. Schematics 
of particle formation in the aerosol flow reactor method are shown in Figure 5.  
 
Figure 5. Schematics of particle formation in the aerosol flow reactor method. 
The aerosol flow reactor method has previously been used for the manufacture 
of micronsized drug particles [211]. For the purposes of this thesis, the 
experimental set-up was modified with an atomiser producing nanosized 
droplets and a collection device capable of separating nanosized particles from 
the carrier gas. The experimental set-up used in this study is shown in Figure 6.  
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Good reproducibility of the aerosol flow reactor method was found by 
performing several experiments at the same conditions. The results were 
repeatable, and significant variation was not observed. 
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Figure 6. Experimental set-up used in the preparation of nanoparticles (N2 = 
clean, dry pressurized nitrogen, Vac. = vacuum, l/min = standard litres per 
minute, Kr-85 aerosol neutraliser using 85Kr β-source, DMA = differential 
mobility analyser, CPC = condensation particle counter) (II, IV, V). 
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4.1.1 Starting solution and atomisation 
4.1.1.1 Preparation of the starting solution 
The solution containing the drug and the polymer was prepared as the first step 
of the particle preparation. Usually, the drug-polymer solution was prepared by 
separately dissolving the polymer and the drug into a single solvent and then 
mixing the solutions at various ratios (III, IV, V). To ensure the homogeneity of 
the droplets in the atomisation, the starting solution should also be 
homogeneous. Ethanol was used as the solvent (III, IV, V), as ethanol is a good 
solvent for the polymers and the drugs studied, as well as non-toxic and 
pharmaceutically acceptable. Also, the solvent and the solvent composition were 
varied to analyse the effects of solvent properties on particle morphology (II). 
4.1.1.2 Atomisation of the solution 
Aerosol was generated by the atomisation of the solution using a collision-type 
air jet atomiser as the aerosol generator (TSI 3076, TSI Inc. Particle Instruments, 
St. Paul, USA). This type of an atomiser is capable of producing droplets within 
the suitable submicron size range, having a geometric number mean diameter of 
approximately 300 nm [212]. 
4.1.2 Solvent evaporation 
The nanosized droplets generated by the atomiser were carried with an inert 
carrier gas, dry nitrogen, into a heated tubular vertical laminar flow reactor. The 
solvent was evaporated from the droplets and solid particles were formed. The 
reactor tube was made of stainless steel with an inner diameter and a heated 
length of 30 mm and 800 mm, respetively. The temperature of the tube could be 
accurately controlled with four heaters. The temperatures used in the 
experiments were varied between 40 °C and 200 °C, each heater controlled to 
same temperature. 
 38 
4.1.2.1 Temperature and flow in the tubular reactor tube 
Computer fluid dynamics calculations of the reactor tube were performed for 
carrier gas flow rates of 1.5 and 3.5 l/min with temperatures covering the 
temperature range used in the experiments. The calculations showed that in the 
heated zone a fully developed laminar flow was achieved, and the wall 
temperature was reached by all particles [213, 214]. Figure 7 shows an example 
of the temperature distribution in the reactor tube. The calculation was 
axisymmetric with gravity pointing towards the left and aerosol flow in the 
opposite direction. The upper portion of the figure shows temperature contours 
and the lower shows axial velocity contours.  
 
Figure 7. Temperature (t (K), upper part) and velocity contours (u (m/s), lower 
part) in the aerosol flow reactor, 80 °C temperature, 1.5 l/min carrier gas flow 
rate. Courtesy of David P. Brown (published with permission) [213, 214].  
4.1.3 Particle sampling and collection 
The nanoparticle aerosol was diluted in a porous tube aerosol diluter before 
sampling or collection (dilution ratio 1:17, dilution gas nitrogen at 50 °C (I, III) 
or 20 °C (II, V)). 
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Particle sampling was done directly from the diluted aerosol for particle size 
measurements using a differential mobility analyser (I, II, III, IV, V) and for 
particle morphology analyses using an electrostatic precipitator (I, II).  
A Berner-type low-pressure cascade impactor was chosen for bulk collection of 
the particles (III, IV, V), as this impactor has cut-off sizes in the suitable size 
range from 30 nm to 15 µm [215]. The impactor collected and separated the 
particles according to their aerodynamic particle sizes to 11 stages. The 
nanoparticles were collected with the impactor onto aluminium foils and 
combined to form the dry powder samples (III, IV, V). 
4.2 Materials 
4.2.1 Drug materials 
Drug materials used in this study were chosen from two different groups of 
materials. Firstly, poorly water soluble drug of corticosteroid-type chemical 
structure, beclomethasone dipropionate, was studied (I, III). Two other drug 
materials studied, ketoprofen (IV, V) and naproxen (IV), belong to a wide group 
of non-steroidal anti-inflammatory drugs. These chosen drugs have been 
previously studied in various micro- and nanoparticle systems [102, 122, 163, 
216222]. The physicochemical properties and the chemical structures of the 
studied drug materials are given in Table 2 and Scheme 1, respectively. 
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Table 2. Physicochemical properties of the drug materials studied. 
 Beclomethasone 
dipropionate 
Ketoprofen Naproxen 
Molecular formula C28H37ClO7 C16H14O3 C14H14O3 
Chemical name 9-Chloro-11β,17,21-
trihydroxy-16β-
methylpregna-1,4-diene-
3,20-dione 17,21-
dipropionate 
(2RS)-2-(3-
benzoylphenol) 
propanoic acid 
(2S)-2-(6-
mathoxynaphthalen- 
2-yl)propanoic acid 
CAS number [5534-09-8] [22071-15-4] [22204-53-1 ] 
Molecular weight (g/mol) 521.05 254.28 230.26 
Solubility in water (mg/l) 150 (at 37 °C) [223] 118 (at 25 °C) [224] 
51 (at 22 °C) [225] 
14 (at 25 °C) [224] 
16 (at 25 °C) [225] 
Solubility at pH 1.2 (mg/l)  130 [96] 5 [96] 
Solubility at pH 5.0 (mg/l)  840 [96] 90 [96] 
Solubility at pH 7.4 (mg/l)  > 1400 [96] > 2500 [96] 
Biopharmaceutical 
classification system class 
 II (at pH 1.2) [96] 
I (at pH 7.4) [96] 
II (at pH 1.2) [96] 
I (at pH 7.4) [96] 
pKa  3.98 [224] 4.18 [224] 
Melting temperature (°C) 212 (measured) 97 (measured) 158 (measured) 
Glass transition temperature 
(°C) 
66 (calculated) [125, 
138] 
-14 (calculated) [125, 
138] 
-2 (measured) 
29 (calculated) [125, 
138] 
Particle size, 90% less than 
(µm) 
6 (measured) 19 (measured)  
Particle size, 99% less than 
(µm) 
9 (measured) 42 (measured)  
Density (g/(cm)3) 1.36 [226] 1.28 [227] 1.27 [228] 
Molar volume ((cm3)/mol) 383 (calculated) 199 (calculated) 182 (calculated) 
Unit cell Orthorhombic [226] Triclinic [227] Monoclinic [228] 
Unit cell dimensions a = 12.12 Å [226] 
b = 14.13 Å 
c = 14.84 Å 
α = 90 ° 
β = 90 ° 
γ = 90 ° 
a = 3.89 Å [227] 
b = 7.74 Å 
c = 6.14 Å 
α = 89.6 ° 
β = 94.6 ° 
γ = 88.8 ° 
a = 13.32 Å [228] 
b = 5.78 Å 
c = 7.87 Å 
α = 90 ° 
β = 93.9 ° 
γ = 90 ° 
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Scheme 1. Chemical structures of the drug materials studied.  
4.2.2 Polymer materials 
The polymers used in this work were chosen from pharmaceutically acceptable 
materials, which have been used for oral formulations. Three different 
copolymers were studied in this work, namely, methacrylic polymers Eudragit L, 
Eudragit E, and Eudragit RS. The properties and the chemical structures of the 
polymers are shown in and Scheme 2, respectively [161, 162].  
For the purposes of this study, it was assumed that these polymers are random 
copolymers. Copolymerisation behaviour can be predicted from the reactivity 
ratios of the monomers [143]. In an ideal copolymerisation, the distribution of 
the monomers in the polymer chain is random [143]. The reactivity ratios of the 
monomers were estimated using the Q-e scheme [143, 229]. For the 
copolymerisation of methyl methacrylate and methacrylic acid the reactivity 
ratios r1 and r2 were calculated to be 0.87 and 1.10, respectively [143, 229]. For 
this polymerisation, r1r2 = 0.96 ≈ 1, hence it can be stated that the polymerisation 
is ideal [143]. Similarly, for the copolymerisation of methyl methacrylate and 
butyl methacrylate r1 and r2 were calculated to be 0.91 and 1.09, resulting in r1r2 
= 0.99 ≈ 1 [229]. For the copolymerization of methyl methacrylate and ethyl 
acrylate r1 and r2 were calculated to be 2.02 and 0.48, resulting in r1r2 = 0.97 ≈ 1 
[229]. For these three monomer pairs, the copolymerizations can be regarded as 
ideal and the copolymers formed have a random placement of the monomers in 
the polymer chain [143]. Therefore, the assumption that the polymers used are 
random copolymers should be acceptable. Unfortunately, the values of Q-e 
scheme could not be found for the monomers (2-dimethylaminoethyl) 
methacrylate and trimethylammoniumethyl methacrylate chloride.  
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Table 3. Physicochemical properties of the polymer materials studied. 
 Eudragit L 100 Eudragit E 100 Eudragit RS 100 
Composition Poly(methacrylic acid, 
methyl methacrylate) 
1:1 [161] 
Poly(butyl methacrylate,  
(2,2-dimethylaminoethyl) 
methacrylate, methyl 
methacrylate) 1:2:1 [161] 
Poly(ethyl acrylate,  
methyl methacrylate, 
trimethylammoniumet
hyl methacrylate 
chloride) 1:2:0.1 [161] 
Water solubility Soluble at pH ≥ 6 [161] Soluble at pH ≤ 5 [161] Not soluble 
Not pH-dependent 
Tg (°C) 67 (measured) 45 (measured) 64 (measured) 
Density (g/(cm)3) 0.83-0.85 [161] 0.81-0.82 [161] 0.815-0.835 [161] 
Mw (g/mol) 115000 [230] 23500 (measured) 39000 [231] 
Polydispersity 
(Mw/Mn) 
2.0 [230] 1.9 (measured) 1.5 [231] 
 
 
Scheme 2. Chemical structures of the polymer materials studied. 
4.3 Instrumentation and characterisation 
Particle morphology (I, II, III, IV, V) was analysed using a scanning electron 
microscope (SEM, Leo DSM982 Gemini, LEO Electron Microscopy Inc., 
Oberkochen, Germany). Samples were prepared onto copper grids (Agar 
Scientific Ltd., Essex, England) or onto copper grids coated with carbon film 
(Agar Scientific Ltd., Essex, England) either directly from gas-borne particles 
using an electrostatic point-to-plane precipitator (InTox Products, Albuquerque, 
USA) or from collected dry powders by gently dipping the sample grid into the 
powder and carefully blowing off excess material. 
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Internal structure of the particles (I, III, IV, V) was studied using a transmission 
electron microscope (TEM, Philips CM200 FEG, FEI Company, Eindhoven, the 
Netherlands). The samples were prepared onto copper grids coated with carbon 
film (Agar Scientific Ltd., Essex, England) as described for scanning electron 
microscopy. 
Particle size distributions of the nanoparticles (I, II, III, IV, V) were analysed 
directly from the aerosol using a scanning mobility particle sizer (SMPS) 
equipped with a long differential mobility analyser (DMA, model 3071 or model 
3081, TSI Inc. Particle Instruments, St. Paul, USA) and a condensation particle 
counter (CPC, model 3022 or model 3027, TSI Inc. Particle Instruments, St. 
Paul, USA).  
Particle sizes of beclomethasone dipropionate and ketoprofen starting powder 
materials were determined using an optical microscope (Olympus AH-2, 
Olympus Optical Co. (Europa) GmbH, Hamburg, Germany) equipped with a 
digital camera (Colorview 12, Soft Imaging System GmbH, Münster, Germany) 
and an image analysis program (AnalySIS Pro, v. 3.1, Soft Imaging System 
GmbH, Münster, Germany). A small amount of powder was dispersed in liquid 
paraffin and the resulting suspension was spread onto microscope slide. The 
particle size of beclomethasone dipropionate was analysed using interactive 
analysis and magnification of 600x, while the particle size of ketoprofen was 
determined using automatic analysis and magnification of 200x.  
The thermal properties of the prepared particles (III, IV, V) were studied using a 
differential scanning calorimeter (Mettler Toledo DSC 822e, Mettler Toledo 
AG, Greifensee, Switzerland) equipped with a Stare computer program. 
Approximately 3 mg of sample was accurately weighed into a 40 µl aluminium 
pan and sealed with a punched lid. The samples were heated from 25 °C to 300 
°C (III) or from -50 °C to 200 °C (IV, V) using a heating rate of 10 °C/min. A 
nitrogen purge of 50 ml/min was used in the oven.  
Glass transition temperature was determined as the midpoint temperature of the 
glass transition, as shown in Figure 8 for exemplary curves [127]. The 
transitions observed were verified as glass transitions by heating-cooling-heating 
experiments of pure polymers. 
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Figure 8. Determination of glass transition temperatures for exemplary curves. 
A) Nanoparticles containing 25% (w/w) ketoprofen / 75% (w/w) Eudragit E, B) 
Nanoparticles containing 0% (w/w) ketoprofen / 100% (w/w) Eudragit L. 
The thermal properties of the materials were also studied using an optical 
microscope (III) (Zeiss Axioskop, Oberkochen, Germany) equipped with a 
heating stage (Linkam THMS 600, Surrey, England) and a temperature 
controller (Linkam TMS 92, Surrey, England). The heating rate used was 20 
°C/min.  
The crystallinity of the particles was studied using X-ray diffraction (III, IV) 
(control unit Philips PW 1710, Philips, Eindhoven and Almelo, The 
Netherlands) with Cu Kα radiation (generator PW 1830, 40 kV, 50 mA, α1 
wavelength 0.154060 nm, α2 wavelength 0.154439 nm with an α1/α2 ratio of 
0.5). Diffraction angles (2θ) (goniometer PW 1820) used in the recording of the 
XRD patterns were 340°. 
The amount of the drug incorporated in the nanoparticles (III, IV) was analysed 
using a spectrophotometer (Pharmacia LKB Ultrospec III, Pharmacia LKB 
Biochrom Ltd., Cambridge, England (III, IV)). A suitable amount of 
nanoparticles was dissolved, the absorbance of the drug at a specific wavelength 
was measured, and the concentration of the solution was assessed from a 
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calibration line based on Beer-Lambert law [232]. Beclomethasone dipropionate 
concentration was measured using wavelength 239 nm [223]. It was observed 
that Eudragits also show a small absorption at the same wavelength, so for every 
sample a background measurement was done with an ethanolic solution 
containing the same amount and type of Eudragit as the sample. Ketoprofen and 
naproxen concentrations were analysed using wavelengths 255 nm [233] and 
271 nm [234], respectively. Eudragit materials did not interfere with the 
measurements at these wavelengths.  
Drug release tests of nanoparticles containing ketoprofen (IV, V) were 
performed using a method based on the general drug release standard of US 
Pharmacopeia for delayed-release (enteric-coated) articles, method A [235]. An 
amount of nanoparticles corresponding to approximately 2 mg of drug was 
weighed. Erlenmeyer flasks (IV) or round-bottomed cylindrical glass vessels (V) 
were used as release chambers. The solutions were stirred using a magnetic 
stirrer at a speed of 100 rpm (IV) or 50 rpm (V). The temperature was either 
ambient (IV) or controlled to 37.0 ± 0.5 °C (V). In the acid stage, 75 ml of 0.1 N 
hydrochloric acid was used as the release medium. Aliquots were withdrawn at 
predetermined time intervals and immediately replaced with fresh medium 
equilibrated at 37 °C. After two hours, 25 ml of 0.2 M tribasic sodium phosphate 
was added to change the pH of the test medium to 6.8. The test was continued 
for further three (IV) or four (V) hours. The amount of the drug released was 
determined after filtration using a spectrophotometer (Philips PU 8620 Series 
UV/VIS/NIR, Pye Unicam Ltd., Cambridge, England (IV) or Pharmacia LKB 
Ultrospec III, Pharmacia LKB Biochrom Ltd., Cambridge, England (V)) using 
wavelength 260 nm for ketoprofen [233] and 270 nm for naproxen [234]. The 
concentration of drug in the acid stage was 0.027 mg/ml, whereas the ketoprofen 
solubility in acid conditions is stated to be 0.13 mg/ml [96]. Therefore, sink 
conditions were achieved. The tests were performed with two parallel runs, the 
values reported are mean values of the two runs. The repeatability of the method 
was evaluated by analysing six parallel samples, and it was found that the results 
are repeatable. The measured dissolution values have a standard deviation of 6% 
on average, while the maximum standard deviation was less than 10%. The 
highest standard deviation values were observed immediately after the pH 
change, probably due to incomplete mixing and equilibration of the pH in the 
dissolution vessel. 
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Drug release tests of nanoparticles containing beclomethasone dipropionate were 
performed in an aqueous medium containing 0.1 % (w/w) sodium lauryl 
sulphate. An amount of nanoparticles corresponding to approximately 0.5 mg of 
drug was weighed. Round-bottomed cylindrical glass vessels were used as 
release chambers. The solutions were stirred using a magnetic stirrer at a speed 
of 100 rpm. The temperature was controlled to 37.0 ± 0.5 °C. Aliquots were 
withdrawn at predetermined time intervals and immediately replaced with fresh 
medium equilibrated at 37 °C. The amount of the drug released was determined 
using a spectrophotometer (Pharmacia LKB Ultrospec III, Pharmacia LKB 
Biochrom Ltd., Cambridge, England) using wavelength 240 nm [223]. The tests 
were performed with two parallel runs, the values reported are mean values of 
the two runs. 
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5. Results 
5.1 Particle size, particle size distribution, and 
particle morphology (I, II, III, IV) 
5.1.1 Particle size and particle size distribution as a function of 
solution concentration (IV) 
The atomiser used produces a lognormal droplet size distribution with a 
geometric number mean droplet size of approximately 300 nm and a geometric 
standard deviation between 1.6 and 2.0 [212]. In the beginning of the droplet 
drying, the evaporation of the solvent leads to supersaturation in the droplet, 
causing precipitation of the solid material. Each of the droplets is transformed 
into a solid particle. The droplet size distribution, and consequently, also the 
resulting particle size distribution, is determined by the atomisation [236]. It was 
assumed that the resulting particle size, or specifically, particle volume, should 
be dependent on the solution concentration. The size and the size distribution of 
the nanoparticles were studied as a function of starting solution concentration 
(IV). When the solution concentration was increased, the particle size was also 
increased (see Figure 9), but the width of the size distribution remained 
unchanged. The lognormal droplet size distribution generated by the atomiser 
was reflected in the resulting particle size distributions. 
 
Figure 9. Particle size distributions for the various starting solution 
concentrations (IV). 
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The geometric number mean particle diameter is shown as a function of starting 
solution concentration in Figure 10. In addition, the mean particle volume was 
calculated from the geometric mean particle diameter using the formula  
3
6
1 dV π= , 
where V denotes the particle volume and d the particle diameter. It can be seen 
that the particle volume was linearly dependent on the concentration of the 
solution (see Figure 10). Deviations from a perfectly linear behaviour are likely 
to be caused by changes in solution viscosity due to changing concentration, 
which affects the atomisation [237].  
 
Figure 10. Geometric number mean diameter and calculated particle volume as 
a function of starting solution concentration. The dashed line represents linear 
least squares fit of particle volume data points (r2 =0.99070) (IV).  
5.1.2 Particle size and particle morphology (I, II, III) 
5.1.2.1 Effect of temperature (I, III) 
The effect of drying temperature on particle size and particle morphology was 
studied for the nanoparticles containing only drug (I, III) or both drug and 
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polymer (III). The preparation of the nanoparticles containing only drug was 
studied using BDP as the model drug. The temperature used in the procedure 
was varied from 40 °C to 180 °C. Within the temperature range of 40 °C to 
140 °C, the particle size did not change significantly (see Figure 11). Also, SEM 
studies showed that at these conditions solid, spherical drug nanoparticles were 
produced. When the drying temperature was increased up to 160 °C, a 
significant increase in the particle size was observed (see Figure 11). In good 
accordance with the particle size measurements, the SEM and TEM studies 
evidenced the formation of hollow, spherical particles (see Figure 12). Similar 
behaviour was also observed for naproxen nanoparticles (not published) in the 
temperature range of 120 °C to 150 °C, below naproxen melting temperature. 
For ketoprofen, hollow particle formation was not observed (not published), 
most likely due to its low melting temperature. Ketoprofen has a melting 
temperature of 97 °C, and therefore, at the temperatures which are required for 
hollow particle formation, ketoprofen is not in a solid state.  
 
Figure 11. Geometric number mean diameter of the nanoparticles containing 
various amounts of drug and polymer as a function of temperature. Total 
concentration of solids was 1 g/l (III). 
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Figure 12. TEM image of a hollow BDP nanoparticle produced (I). 
Hollow particle formation is commonly achieved using fast heating rates, i.e. 
high drying temperatures and rapid solvent evaporation, whereas slower heating 
rates favour the formation of dense particles [238, 239]. Fast evaporation of the 
solvent creates a high supersaturation of the solute at the surface of the droplets. 
If the diffusion of the solvent to the surface is slow, the supersaturation causes 
precipitation of the material to create a solid crust [200, 236, 239242]. If the 
crust formed is permeable to the solvent, diffusion of the solvent and the solute 
in the droplet can lead to spherical, solid particles [164]. If the crust is 
impermeable to solvent, the particle will form a hollow interior due to pressure 
build-up on further solvent evaporation, which expands the particle [200, 236]. 
Hollow spherical particles can also collapse to raisin- or lens-shaped particles 
[164, 202, 242, 243]. The formation of hollow particles is, in addition to fast 
heating rate, also promoted by using concentrated solutions and large droplet 
size according to the literature [240, 244]. Mechanisms of formation of solid and 
hollow particles are summarised in Figure 13.  
When the nanoparticles were prepared from polymer and drug, the particles 
were observed to be spherical, solid, and amorphous when sampled with a point-
to-plane electrostatic precipitator from nanoparticle aerosol and studied with 
TEM (not published). The drying temperature did not have an effect on the size 
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or the morphology of the nanoparticles containing polymer (see Figure 11) as 
opposed to the particles containing only drug without any polymer. The 
nanoparticles containing only 20% (w/w) polymer showed similar behaviour to 
the pure polymer nanoparticles (see Figure 11). The polymeric component, even 
in low amounts, determined the structure of the particles.  
5.1.2.2 Effect of solvent system (II, III) 
The influence of the solvent properties and the solvent composition on the 
morphology of the polymer nanoparticles was studied. When the particles were 
prepared from a good solvent for the polymer, the temperature used and thereby 
also the evaporation rate of the solvent determined the morphology of the 
particles. In this case, the interactions between the solvent and the polymer are 
strong, the polymer is well soluble into the solvent even in the later stages of 
evaporation, and spherical particles are obtained (see Figure 13). Moreover, the 
evaporation rate can be also controlled by the vapour pressure of the solvent, the 
solvent having a higher vapour pressure leading to faster evaporation. 
When a poor solvent is added into the solution, the interactions between the 
polymer and the solvent are weakened. During the evaporation stage, the more 
volatile component of the solvent mixture is evaporated first, so the composition 
of the solvent mixture is constantly changing. The good solvents for the polymer 
used (II) are more volatile than the poor solvent, water, so the solvent 
composition changes towards poorer during evaporation. The solute has a 
tendency to precipitate at an early stage during solvent evaporation as the 
polymer-polymer interactions become more favourable than the polymer-solvent 
interactions. Due to sudden precipitation of the polymer, the particle appearance 
is wrinkled or shriveled instead of spherical. Similar results have been found 
previously in spray-drying experiments [164, 239]. The effect of solvent quality 
on the particle formation is shown schematically in Figure 13. Exemplary 
images of particles prepared from a good solvent and a solvent mixture 
consisting of a good and a poor solvent are shown in Figure 14. It was further 
verified that the polymer controlled the particle morphology, as the particle 
morphology did not change on addition of drug in the nanoparticles.  
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Figure 14. SEM images of polymer nanoparticles containing 50% (w/w) 
Eudragit L and 50% (w/w) BDP. The nanoparticles were prepared from A) a 
good solvent (ethanol) or B) a mixture of a good solvent (ethanol) and a poor 
solvent (water). Nominal magnification 50000x. 
5.2 Collection and properties of bulk nanoparticle 
powder (III, IV, V) 
5.2.1 Collection of the nanoparticles (III, IV, V) 
5.2.1.1 Nanoparticles containing ketoprofen or naproxen (IV) 
The nanoparticles produced are amorphous due to rapid evaporation of the 
solvent from the droplets. Nonetheless, the stability of the nanoparticles in the 
amorphous form as dry powder during collection and storage is not necessarily 
achieved. The amorphous form of the drug incorporated has a tendency to 
spontaneously convert to a crystalline form [128, 129]. This was studied for 
various drug-polymer systems, with particular interest on the nanoparticles 
containing ketoprofen. Firstly, small drug molecules such as naproxen and 
ketoprofen were observed to be very unstable showing sintering of the 
nanoparticles and subsequent drug crystal growth in collection when polymer 
was not incorporated in the nanoparticles. Therefore, the use of polymers in the 
nanoparticles was found necessary to stabilise the amorphous particle structure 
against drug crystal growth. 
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It was found that when the amount of ketoprofen drug in the polymer 
nanoparticles was small, the particles produced and collected with the BLPI 
were amorphous (IV, V), see the XRD patterns (Figure 15), DSC measurements 
(Figure 16), and TEM image (Figure 17). In Figure 15, diffraction patterns of 
nanoparticles with two compositions are shown in addition to a diffraction 
pattern of untreated drug powder. When the amount of the drug was small, the 
XRD showed an amorphous pattern and no crystallinity (curve C of Figure 15). 
Figure 16 shows DSC scans for untreated drug powder and various compositions 
of nanoparticles. In good accordance with the XRD studies, crystallinity could 
not be detected by DSC when the amount of the drug was small, as peaks 
corresponding to the melting of the drug crystals were not observed. Amorphous 
structure was obtained when the amount of the drug was equal to or less than 33 
% (w/w) (curve C of Figure 16). The amorphous nanoparticles prepared were 
also studied using TEM, and a typical image is shown in Figure 17. Crystallinity 
or grain boundaries were not found, instead, the nanoparticles were smooth with 
a uniform interior. Furthermore, typical SEM image of the prepared 
nanoparticles is shown in Figure 18 as image A. The nanoparticles were 
spherical and smooth, and major necking was not observed. The formation of an 
amorphous polymer-drug structure has previously been observed for spray-dried 
particles containing methacrylic polymers and ketoprofen drug [218, 219].  
When the amount of ketoprofen in the nanoparticles was increased up to 50 % 
(w/w) an endothermic transition corresponding to melting of the drug crystals 
was detected at 93.1 °C in DSC (curve B of Figure 16). Moreover, in the XRD 
analyses, the broad background diffraction pattern of the amorphous structure 
became overlapped by peaks corresponding to the diffraction from the drug 
crystal lattice. The strongest diffraction peaks of crystalline ketoprofen at 6.4° 
(2θ) and 23.0° (2θ) can be identified in the diffraction curve of the nanoparticles 
containing 50% (w/w) ketoprofen (curve B of Figure 15). The TEM imaging 
further confirmed the formation of large crystalline structures. The collected 
nanoparticles coalesced, which was followed by drug diffusion in the polymer 
matrix and crystal growth between and out of the composite nanoparticles, as 
shown in the SEM image C in Figure 18.  
Similar results were found also for the nanoparticles containing naproxen (see 
Figure 18, images B and D). However, for naproxen, only nanoparticles 
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containing 10% (w/w) naproxen were found to be amorphous, and crystals were 
observed to appear when the nanoparticles contained 25% (w/w) naproxen (IV).  
 
Figure 15. X-ray diffraction patterns of the nanoparticles. A) Untreated 
ketoprofen. B) 50% (w/w) ketoprofen / 50% (w/w) Eudragit L nanoparticles. C) 
25% (w/w) ketoprofen / 75% (w/w) Eudragit L nanoparticles. Curve A was 
reduced by a factor of 4 to fit in the same image. The curves are shifted along y-
axis for clarification (IV). 
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Figure 16. Differential scanning calorimetry thermograms of the nanoparticles. 
A) Untreated ketoprofen. B) 50% (w/w) ketoprofen / 50% (w/w) Eudragit L 
nanoparticles. C) 33% (w/w) ketoprofen / 67% (w/w) Eudragit L nanoparticles. 
D) 25% (w/w) ketoprofen / 75% (w/w) Eudragit L nanoparticles. E) 10% (w/w) 
ketoprofen / 90% (w/w) Eudragit L nanoparticles. F) 100 % (w/w) Eudragit L 
nanoparticles. Curve A was reduced by a factor of 20 to fit in the same image. 
The curves are shifted along y-axis for clarification (IV). 
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Figure 17. TEM image showing amorphous, spherical nanoparticles prepared. 
Nanoparticles containing 25% (w/w) ketoprofen and 75% (w/w) Eudragit L. 
Electron optical magnification 5600x (IV).  
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Figure 18. Exemplary SEM images of the collected nanoparticle powders. A) 
Nanoparticles containing 33% (w/w) ketoprofen and 67% (w/w) Eudragit L. 
Nominal magnification 50000x. B) Nanoparticles containing 10% (w/w) 
naproxen and 90% (w/w) Eudragit L. Nominal magnification 50000x. C) 
Nanoparticles containing 67% (w/w) ketoprofen and 33% (w/w) Eudragit L. 
Nominal magnification 10000x. D) Nanoparticles containing 67% (w/w) 
naproxen and 33% (w/w) Eudragit L. Nominal magnification 10000x (IV).  
Schematics of the various drug-polymer structures that can be formed in the 
particle collection are shown in Figure 19. The nanoparticles, when first formed, 
are amorphous due to rapid solvent evaporation. The amorphous structure can 
either be stable, as shown as route A of Figure 19, or show crystallisation at 
ambient temperature (route D) or on heating (route B-C) due to drug molecule 
diffusion in the polymer matrix. When the system is amorphous, as is the case 
for the nanoparticles containing 33% (w/w) or less ketoprofen, the particle 
structure follows the route A, and stable amorphous nanoparticles at ambient 
temperature can be collected. However, when the amount of the drug is 
increased, the solubility limit of the drug in the polymer matrix is exceeded and 
the crystallisation of the drug at ambient temperature is observed as shown as 
route D. 
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Figure 19. Schematics of the drug-polymer structures formed in particle 
collection.  
In the amorphous structure, the drug is solubilised by the polymer and the two 
components form an amorphous solid solution [144]. The interactions between 
the drug and the polymer molecules determine the solubility of these materials in 
each other [245]. When the drug-polymer molecular interactions are comparable 
 60 
to the drug-drug and the polymer-polymer interactions, the drug is well 
solubilised by the polymer and large amounts of drug can be incorporated in the 
polymer matrix without drug crystallisation [145]. However, when the drug-
polymer interactions are weaker than the drug-drug or the polymer-polymer 
interactions, the drug and the polymer have a preference to interact with the 
molecules of their own kind, leading to a potential for drug crystallisation. A 
small amount of drug, below the solubility limit of the drug in the polymer, can 
be solubilised by the polymer matrix [147, 246]. On increasing the amount of the 
drug over this limit, the drug is no longer soluble in the amorphous polymer, but 
can form separate crystallites [159].  
The polymer nanoparticles consisting of Eudragit L were found to be able to 
contain 33% (w/w) ketoprofen in an amorphous form, but only 10% (w/w) 
naproxen. The solubilities of the drug molecules ketoprofen and naproxen in 
Eudragit L were estimated based on DSC measurements. The enthalpy of 
melting was determined for untreated, pure drug, which was taken to be 100% 
crystalline. The enthalpy of melting of unsolubilised drug was analysed for the 
nanoparticles, in which first crystals were found to appear, namely, the 
nanoparticles containing 50% (w/w) ketoprofen and 25% (w/w) naproxen. It was 
further assumed that the drug crystals formed in the nanoparticles were 100% 
crystalline. The amount of crystallised drug wc can then be calculated as a ratio 
%100
m
m
c H
Hw
∆
∆
= , 
where ∆Hm is the enthalpy of melting of the sample studied, and ∆Hm100% is the 
enthalpy of melting of 100% crystalline material [247]. For ketoprofen, the 
enthalpies of melting of pure drug and 50% (w/w) nanoparticles were measured 
to be 114.9 J/g and 1.1 J/g, respectively. For 50% (w/w) nanoparticles, the 
amount of crystallised drug was thus determined to be 1%. Therefore, the 
solubility of ketoprofen in Eudragit L can be estimated as  
( ) ( ) ( )w/w 49.5%0.011w/w 50% =−⋅ , 
which corresponds to  
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( ) g/g 0.98%49.5100
49.5%
=
−
, 
meaning that 1 gram of polymer can solubilise 0.98 g ketoprofen. Similarly, for 
naproxen, the enthalpies of melting of pure drug and 25% (w/w) nanoparticles 
were measured to be 125.8 J/g and 4.5 J/g, respectively. The solubility of 
naproxen in Eudragit L can then be estimated to be 24.1% (w/w), corresponding 
to 0.32 g/g.  
The differences in the behaviours of these materials are likely to be caused by 
interactions between the drug and the polymer as well as different molecular 
structures of the drugs studied [140, 141]. Firstly, crystallisation of the drug 
requires the diffusion of drug molecules and their arrangement into a crystal 
lattice. Diffusion of the drug in the polymer matrix has been shown to be a 
function of the molar volume of the drug, larger molecules having smaller 
diffusion coefficients and slower diffusion [248, 249]. Also, the interactions 
between the drug and the polymer affect the diffusion of drug in the polymer 
matrix, the stronger the interactions, the slower the drug diffusion [248]. It can 
be speculated that the drug molecules ketoprofen and naproxen should have 
similar diffusion coefficients, as the molar volumes of the drugs are fairly 
similar, namely 199 (cm)3/mol for ketoprofen and 182 (cm)3/mol for naproxen 
(calculated from density of crystalline material, see Table 2). Moreover, both 
drug molecules can interact with the polymer by the same functional group, 
carboxylic acid, so the interactions caused by this group should not differ in 
magnitude. The difference of these two molecules lies in the molecular structure, 
naproxen having a stiff naphthyl ring system in comparison to more flexible 
ketoprofen drug molecule. This difference is also reflected in the melting points 
of the drugs, as the more mobile and flexible molecule ketoprofen has a lower 
melting point than the stiffer naproxen molecule. 
An analogy to the solubility of the drug in the polymer can be found from 
plasticisation, where flexible small molecules are mixed with the polymer to 
lower the Tg [146, 159, 245, 250]. Also in plasticisation, it is essential that the 
plasticising agent forms a uniform mixture with the polymer, and is solubilised 
by the polymer. Consequently, from this point of view, ketoprofen was a more 
effective plasticising agent for the Eudragit L polymer than naproxen [159]. 
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5.2.1.2 Interactions between ketoprofen and methacrylic polymers (V) 
The plasticising effect of ketoprofen was verified in the differential scanning 
calorimetry analyses showing depression in the Tg of polymers Eudragit L, 
Eudragit RS, and Eudragit E as a function of increasing drug amount in the 
nanoparticles (see Table 4 and Figure 20) (V). Crystallisation of the drug was 
not found for the nanoparticles prepared from the cationic polymer Eudragit RS 
or the basic polymer Eudragit E, in comparison to the acidic polymer Eudragit L. 
However, as the Tg was lowered close to the room temperature for the former 
two polymers, separate nanoparticles having more than 10% (w/w) of drug could 
not be collected with BLPI. SEM observations evidenced coalesced particles 
(see Figure 21). The nanoparticles prepared from the polymers Eudragit E and 
Eudragit RS followed the route A of Figure 19, but the glass transition was so 
close to the room temperature that the mechanical integrity of the nanoparticles 
was not maintained. The solubility of ketoprofen in the polymers Eudragit E and 
Eudragit RS is larger than the solubility in the polymer Eudragit L, as drug 
crystallites were not observed with the drug amounts studied. The values of 
solubility in the former two polymers could not be determined based on these 
experiments.  
Table 4. Glass transition temperatures of the nanoparticles prepared from 
ketoprofen and various polymers. a) Also an endothermic transition 
corresponding to the melting of ketoprofen crystals was observed at 94 °C (V). 
Amount of ketoprofen 
(w/w) 
Eudragit L Eudragit E Eudragit RS 
0 % 54 °C 49 °C 53 °C 
5 % 52 °C 45 °C 50 °C 
10 % 50 °C 41 °C 50 °C 
25 % 50 °C 24 °C 28 °C 
33 % 48 °C 23 °C 20 °C 
50 % 40 °C a)   
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Figure 20. Differential scanning calorimetry thermograms of the ketoprofen 
nanoparticles. A) Untreated ketoprofen, B) Nanoparticles containing 50% (w/w) 
ketoprofen, C) Nanoparticles containing 33% (w/w) ketoprofen, D) 
Nanoparticles containing 25% (w/w) ketoprofen, E) Nanoparticles containing 
10% (w/w) ketoprofen, F) Nanoparticles containing 5% (w/w) ketoprofen, G) 
Nanoparticles containing 0% (w/w) ketoprofen. Curve A was reduced by a 
factor of 20 to fit in the same image. The curves are shifted along y-axis for 
clarification (V). 
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Figure 21. Exemplary scanning electron microscopy images of the ketoprofen 
nanoparticles. A) Nanoparticles containing 25% (w/w) ketoprofen and 75% (w/w) 
Eudragit L. Nominal magnification 50000x. B) Nanoparticles containing 10% 
(w/w) ketoprofen and 90% (w/w) Eudragit RS. Nominal magnification 50000x. C) 
Nanoparticles containing 25% (w/w) ketoprofen and 75% (w/w) Eudragit E. 
Nominal magnification 5000x. D) Nanoparticles containing 25% (w/w) ketoprofen 
and 75% (w/w) Eudragit RS. Nominal magnification 10000x (V). 
The glass transition temperature of an ideal two-component system can be 
calculated theoretically using the Gordon-Taylor equation: 
21
)2(2)1(1
)( Kww
TKwTw
T ggmixg +
+
= , 
where Tg(mix) is the glass transition temperature of the two-component mixture, 
w1 and w2 are the weight fractions and Tg(1) and Tg(2) are the glass transition 
temperatures of the components 1 and 2, respectively [129, 251]. K can be 
estimated as a ratio: 
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where ρ1 and ρ2 are the densities of the components 1 and 2 [129, 251]. 
The theoretical glass transitions of the composite nanoparticles over the whole 
composition range were calculated using the Gordon-Taylor equation, and are 
plotted together with the measured experimental values in Figure 22. It was 
found that the composite nanoparticles prepared from Eudragit E or Eudragit RS 
show a glass transition lower than predicted by the Gordon-Taylor equation. 
This can be interpreted as a deviation from ideality, caused by the interactions 
between ketoprofen and these polymers [251]. Ketoprofen interacts with the 
polymers. As a flexible molecule, it can effectively plasticise the polymers by 
separating the chains, thereby lowering the glass transition temperature of the 
polymers [152, 252].  
 
Figure 22. Glass transition temperatures of the nanoparticles containing 
ketoprofen and polymer. For the calculated values, the glass transition 
temperature of the nanoparticles consisting of only polymer was used as the 
polymer glass transition temperature. 
The interactions between ketoprofen and the various methacrylic polymers were 
further evaluated using IR spectroscopy (V). Ketoprofen has a carboxylic acid 
group, which can interact with the functional groups of the polymers. The 
carbonyl peaks in the IR spectra of ketoprofen were recorded at 1694 cm-1 and 
1654 cm-1, and have previously been assigned to dimeric carboxylic acid 
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carbonyl group and ketonic carbonyl group stretching vibrations, respectively 
[253, 254] (see Figure 23). 
Examples of the recorded IR spectra of the nanoparticles are shown in Figure 23. 
Considering first the peaks of the pure polymers, the strong stretching vibration 
of the carbonyl moiety of ester groups can be identified for the Eudragit E and 
Eudragit RS materials at approximately 1724 cm-1 [148]. For the Eudragit E and 
Eudragit RS nanoparticles containing ketoprofen, the position of this peak was 
not changed. However, the peak corresponding to the carboxylic acid group of 
ketoprofen at 1694 cm-1 was not observed in the spectra of the composite 
nanoparticles, whereas the peak arising from the ketone carbonyl at 1654 cm-1 
could be identified. The carboxylic acid group of the ketoprofen molecule 
interacts with the polymers, leading to the disruption of the carboxylic acid 
dimer of the crystalline ketoprofen. When the intermolecular ketoprofen dimer is 
disrupted, the carboxylic acid stretching vibration occurs at higher wavenumbers 
[253, 254], is overlapped by the strong ester vibrations of the polymer, and 
cannot therefore be detected.  
A small shift in the position of the ketone carbonyl vibration of ketoprofen to 
higher wavenumber was observed for the nanoparticles prepared from Eudragit 
RS (see Figure 23). It is assumed that the oxygen of the ketone group, which 
carries a partial negative charge, interacts electrostatically with the cationic 
groups of the polymer. 
 
Figure 23. Exemplary infrared spectra at a wavenumber range of 20001500 
cm-1. A) Pure ketoprofen. B) Nanoparticles containing 33% (w/w) ketoprofen. C) 
Pure polymer. The curves are shifted along y-axis for clarification (V). 
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Eudragit E is a polymer containing secondary amino groups capable of accepting 
a proton from an acidic substance. It was initially assumed that at least a fraction 
of the amino groups of the polymer would be protonated by the acidic drug. The 
peaks corresponding to the amino groups of the polymer have been identified 
previously [255, 256] at 2820 cm-1 and 2770 cm-1. However, any change in the 
position of these peaks was not observed when ketoprofen was incorporated in 
the nanoparticles (see Figure 24). Therefore, it can be concluded that ketoprofen 
drug does not protonate the amino groups, but mainly interacts with the ester 
groups of the Eudragit E polymer, similarly to Eudragit RS.  
 
Figure 24. Exemplary infrared spectra at a wavenumber range of 35002500 
cm-1. A) Pure ketoprofen. B) Nanoparticles containing 33% (w/w) ketoprofen. C) 
Pure polymer. The curves are shifted along y-axis for clarification (V). 
For Eudragit L nanoparticles, glass transition values higher than predicted by 
Gordon-Taylor equation were observed (see Figure 22). The drug was able to 
plasticise the polymer, but not as much as predicted by the theory. When the 
amount of ketoprofen in the polymer matrix was larger than the solubility limit 
of drug in the polymer, excess amount of drug formed separate crystallites.  
Eudragit L polymer contains both carboxylic acid and ester groups and, 
therefore, the IR spectra showed overlapping carbonyl vibrations of the ester 
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group at 1724 cm-1 and the carboxylic acid at 1710 cm-1 [150] (see Figure 23). 
However, when ketoprofen is included in the nanoparticles, this peak is splitted 
into two peaks as a function of increasing amount of the drug. The peak at 
approximately 1724 cm-1 can be attributed to the stretching vibrations of the 
polymer ester group carbonyl, similarly to Eudragit E and Eudragit RS 
polymers. However, the peak at the lower wavenumber is recorded at 1710 cm-1, 
1705 cm-1, 1703 cm-1, 1700 cm-1, 1700 cm-1, and 1699 cm-1 for the nanoparticles 
containing 0% (w/w), 5% (w/w), 10% (w/w), 25% (w/w), 33% (w/w), and 50% 
(w/w) ketoprofen, respectively. This peak can be interpreted as arising due to the 
formation of a dimer from the carboxylic acid groups of the polymer and the 
drug. Due to the formation of the dimer, the vibration of the polymer carboxylic 
acid carbonyl was shifted to lower wavenumbers. 
5.2.1.3 Nanoparticles containing beclomethasone dipropionate (III) 
Nanoparticles were also prepared from a drug material having a glass transition 
temperature higher than ambient temperature (III). In this case, also the drug 
material itself can form a glassy, amorphous state without polymer. Below the 
glass transition temperature, the molecular mobility is slow, and the amorphous 
state is kinetically preserved even though it is not thermodynamically stable. In 
this study, the nanoparticles containing BDP and polymer showed single, 
separate nanoparticles over the whole concentration range even when pure drug 
nanoparticles were collected. The stability of these nanoparticles at room 
temperature was not affected by the amounts of the drug or the polymer on the 
contrary to ketoprofen and naproxen nanoparticles.  
The glass transition temperature of ketoprofen was determined using DSC to be 
-2°C. For BDP and naproxen, however, the determinations were not successful 
due to degradation of the material during melting and rapid crystallisation on 
cooling, respectively. Glass transition temperature of a material can be estimated 
from its melting temperature by applying the rule Tg = 0.7·Tm, where Tg and Tm 
are expressed in Kelvins [125, 138]. The calculated glass transition temperatures 
of the drugs are 66 °C for BDP and 29 °C for naproxen. The calculated value of 
Tg of ketoprofen is -14°C. For ketoprofen, applying the rule Tg = 0.7·Tm gives 
actually quite an accurate estimation for the glass transition temperature. The 
coeffient 0.7 can be specified according to the experimental value as 0.73.  
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The Tg of BDP is higher than the collection temperature and, therefore, these 
drug nanoparticles did not crystallise or coalesce in the collection, corresponding 
to route B of Figure 19. The large size of the BDP molecule contributes to slow 
diffusion in the polymer matrix, further hindering the formation of crystals [248, 
249]. When a system consisting of the amorphous drug material is heated, the 
molecular mobility is increased and crystallisation into a thermodynamically 
more favourable crystalline state can take place as shown in Figure 19 as route 
C. This was verified in DSC measurements. The drug nanoparticles consisting of 
only BDP showed a crystallisation exotherm at 141 °C (see Figure 25). 
Subsequent melting peak of the drug was recorded at 210 °C, similarly to the 
untreated drug powder. For the polymer-drug nanoparticles, the crystallisation of 
the drug was retarded to 155 °C and 164 °C for the nanoparticles containing 
80% (w/w) and 60 % (w/w) of BDP, respectively. The viscous polymer hindered 
the diffusion of the drug molecules, retarding the crystallisation of the drug.  
 
Figure 25. DSC scans of nanoparticles containing various amounts of BDP and 
Eudragit L. A) 100% (w/w) BDP, B) 80% (w/w) BDP / 20% (w/w) Eudragit L, 
C) 60% (w/w) BDP / 40% (w/w) Eudragit L, D) 50% (w/w) BDP / 50% (w/w) 
Eudragit L, E) 100% (w/w) Eudragit L. Observed crystallisation and melting of 
the crystals are marked with cr and m, respectively . The curves are shifted 
along y-axis for clarification (III). 
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5.2.2 Drug release from nanoparticles containing ketoprofen (IV, V) 
To evaluate the effect of the amount of polymer on drug release, release tests 
were performed for nanoparticles containing various amounts of ketoprofen and 
Eudragit L (IV). Firstly, it was found that pristine, untreated ketoprofen drug 
powder was dissolved completely even at the acidic conditions (pH 1.0) (see 
Figure 26) in less than two hours. The release of the drug from the polymer 
nanoparticles was found to be dependent on the amounts of drug and polymer in 
the nanoparticles. When the nanoparticles contained 33% (w/w) ketoprofen, 
90% of the drug content was released at the acidic conditions. The nanoparticles 
containing 25% (w/w) ketoprofen released 80% of their drug content, whereas 
the nanoparticles containing 10% (w/w) ketoprofen released 70% of the 
incorporated drug at the acidic conditions.  
Ketoprofen release could be delayed to some extent, but even with the lowest 
amount of ketoprofen, 70% of drug content was released in the acid stage of the 
test. Therefore, the nanoparticles do not fulfill the criteria of enteric-coated 
articles [235], i.e. only 10% of the drug amount is allowed to be released in the 
acid stage. It is assumed that the drug at or close to the nanoparticle surface can 
dissolve to the medium at the acidic conditions, although the particles did not 
dissolve. The nanoparticles have a large surface area due to their small size. 
Hence, the amount of drug at or close to the surface, which is susceptible to the 
effect of the medium, is large with respect to the amount of drug in the interior 
of the nanoparticles. Common enteric dosage forms are much larger in size, so 
the relative amount of drug at the surface is also smaller. Due to the large 
surface area and the matrix-type characteristic, nanoparticles fulfilling the 
criteria of enteric-coated articles could not be prepared. After the pH change (pH 
6.8), complete dissolution of the nanoparticles took place rapidly, in less than 15 
minutes for all the samples. At the buffer conditions (pH 6.8), the Eudragit L 
polymer is ionised and soluble in the medium, thereby releasing the drug 
immediately.  
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Figure 26. Ketoprofen release for nanoparticles containing various amounts of 
drug as a function of time (IV). Pure ketoprofen denotes untreated, commercial, 
crystalline ketoprofen powder (particle size 90% less than 19 µm). 
Drug release was also studied for nanoparticles prepared from different 
polymers and ketoprofen (see Figure 27) (V). Nanoparticles prepared from 
Eudragit L showed an initial, instant release of approximately 30 % of the drug 
in the acidic stage of the test. However, the drug release was slightly slower than 
of pure ketoprofen. After the pH change, complete dissolution of the 
nanoparticles took place rapidly. At the buffer conditions (pH 6.8), the Eudragit 
L copolymer was ionised and soluble in the medium, thereby releasing the drug 
immediately. The nanoparticles studied contained 10% (w/w) ketoprofen, 
similarly to the nanoparticles studied in Figure 26. The difference in the drug 
release curves of Figure 26 and Figure 27 for the same nanoparticles is most 
likely caused by different conditions used in the two measurements, as the 
results were repeatable in both cases.  
Eudragit E polymer, however, is soluble at the acidic conditions. Complete 
release of the drug was obtained for Eudragit E nanoparticles in the acidic 
medium in less than 15 minutes as a result of polymer dissolution. As the 
polymer dissolved, also the drug contained in the nanoparticles was forced into 
the solution. Drug release from the nanoparticles was much faster than of pure 
ketoprofen (see Figure 27).  
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Eudragit RS nanoparticles showed sustained release of the drug at the acidic 
conditions (pH 1.0), and the drug release was found to be approximately linear. 
Similarly to Eudragit L nanoparticles, approximately 30% of the drug was 
released initially. Further drug release from the nanoparticle matrix was 
controlled by the polymer. When the pH was changed (pH 6.8), the amount of 
the released drug changed rapidly from approximately 60% to almost 80%. At 
the buffer conditions, release of the drug was faster as the ketoprofen molecules 
were ionised. Most likely, the ketoprofen molecules at or close to the surface of 
the nanoparticles could deprotonate at these conditions, and had a greater 
tendency to dissolve. 
 
Figure 27. Ketoprofen release for nanoparticles containing various polymers as 
a function of time. All the nanoparticles studied for drug release contained 10% 
(w/w) ketoprofen (V). Pure ketoprofen denotes untreated, commercial, 
crystalline ketoprofen powder (particle size 90% less than 19 µm). 
The polymer materials Eudragit E and Eudragit L are polyelectrolytes. The 
dissolution mechanism of the polyelectrolytes differs from that of the small 
molecules. The dissolution of an anionic polymer, such as Eudragit L, which 
contains weakly acidic carboxylic acid groups, is considered first. When the pH 
of the medium is below the pKa of the polymer acid groups, the polymer is in the 
collapsed state and is, therefore, not soluble. On increasing the pH, some of the 
acidic units dissociate. When enough groups have attained a negative charge, the 
charges begin to repel each other, and the polymer chain becomes soluble due to 
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ionized carboxylic acid groups and their mutual electrostatic repulsions [257, 
258]. A cloud consisting of counter-ions and co-ions is formed around the 
dissolved polyelectrolyte [259]. The dissolution is represented schematically in 
Figure 28. 
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Figure 28. Schematic representation of dissolution of a polyelectrolyte 
containing carboxylic acid groups (Eudragit L). 
Ketoprofen drug molecules will also attain a negative charge at pH levels higher 
than pKa of ketoprofen, 3.98 [224]. Considering the situation where both the 
polymer and the drug have negative charges, electrostatic repulsion between the 
negatively charged groups separates the drug molecules from the polymer. On 
the contrary, for the basic Eudragit E material, protonation and charge of the 
dimethyl amino groups takes place in the acidic environment. Therefore, the 
polymer chains are rapidly dissolved at the acidic conditions. It is assumed that 
the rapid release of the drug from the particles is achieved due to dissolution of 
the polymer matrix. Provided that the total concentration of the drug in the 
solution is lower that the saturation concentration, the released drug does not 
crystallise, but is maintained in the solution.  
The drug molecule studied is a weak acid, so self-buffering could take place at 
the buffer stage of the test, when the pH of the medium is 6.8. Considering first 
only particles consisting only ketoprofen, most likely the pH at the particle 
surface remains close to the pKa value of ketoprofen (3.98) [115, 116]. Based on 
the results of Figure 26 and Figure 27, the dissolution behavior of the polymers 
is the determining factor for the release of the drug from the nanoparticles 
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containing both drug and polymer. Three different polymers were investigated in 
this study. Polymer Eudragit E is a basic polymer. Therefore, at acidic pH, this 
polymer protonates and attains a positive electrostatic charge. As the hydrogen 
ions are consumed by the protonating polymer, the pH of the dissolving particle 
surface can be higher than the bulk pH. However, when this polymer in the 
nanoparticles is dissolved, the ketoprofen in the particles is forced into the 
solution state. In this case, also the dissolved ketoprofen molecules can protonate 
the polymer. Consequently, an electrostatic interaction takes place between the 
positively charged polymer and negatively charged ketoprofen ions. At pH 6.8, 
the buffer stage, the particles are already dissolved and surface pH can no longer 
be considered relevant.  
Eudragit L is an anionic polymer, similarly to ketoprofen drug molecule. The 
acidic pH used in the study is clearly below the pKa values of the molecules. 
Both the drug molecules and the polymer Eudragit L are almost completely in 
their protonated, neutral forms, and self-buffering can be considered as non-
relevant [115]. When the pH of the bulk is increased to 6.8, self-buffering both 
by the polymer and by the drug molecule can take place. In this case, due to the 
formation of acidic microenvironment around the particles, the release of the 
drug from the particles would be similar to the release at the low pH. At pH 6.8 
used in the study, the drug molecules are almost completely in the ionised form 
according to their pKa value, and are well soluble in the aqueous medium. Also, 
at this pH, the carboxylic acid groups of Eudragit L are deprotonated and the 
polymer is soluble. If self-buffering was to take place, the release rate of the 
drug would be slow. From Figure 27 it can be seen that the drug release rate 
from Eudragit L and Eudragit RS nanoparticles actually increases at pH 6.8. 
Therefore, if self-buffering takes place, its effect on drug release is negligible. 
Eudragit RS is not a water soluble polymer, and it does not show pH-
dependency. At pH 1, self-buffering does not take place. However, at the buffer 
stage of the test, self-buffering by the anionic ketoprofen molecule can take 
place, when the drug molecules slowly diffuse into the water phase.  
From Figure 27, it can be observed that for Eudragit L and Eudragit RS 
nanoparticles, 30% of drug content of the particles is released immediately at the 
acidic conditions. Two possible mechanisms are proposed for the initial 30% 
drug release from Eudragit L and Eudragit RS nanoparticles. Firstly, the 
nanoparticles can contain a larger a proportion of drug at the surface of the 
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particles in comparison to the interior of the particles. Such an uneven 
distribution could arise from diffusion of the small molecules to the particle 
surface during particle preparation and drying process. When such particles are 
immersed in dissolution medium, the drug at the surface is immediately released, 
and only further control of drug release is due to the polymers. Secondly, if the 
dissolution medium can penetrate to some extent to the polymer matrix, the drug 
molecules at and close to the surface will dissolve. Theoretically calculated for a 
100 nm nanoparticle, which has a uniform distribution of drug (10% (w/w)) and 
polymer (90% (w/w)), medium should be able to initially penetrate to 5 nm 
depth to allow 30% drug release. As in the previous case, further control of drug 
release is controlled by the properties of the polymer.  
Dissolution of the drug from an inert matrix can take place by two different 
processes: diffusion of the drug through the matrix into the solution or 
penetration of the solvent into the matrix and subsequent dissolution of drug into 
the penetrated solvent [113, 114, 260]. For the Eudragit RS nanoparticles, the 
drug release takes place by the solvent penetration process. Water slowly 
penetrates in the polymer matrix due to charged quaternary groups, and drug is 
released at a constant rate from the polymer matrix. In comparison, the drug 
release from Eudragit L nanoparticles pauses after the initial burst release of 
30%. Dissolution medium cannot penetrate further into the hydrophobic 
nanoparticles, and additional drug release would have to take place by the drug 
diffusion mechanism. This case can be approximated as consisting of an 
insoluble and non-interacting matrix and a weakly soluble drug dissolved in the 
matrix [261]. However, diffusion of drug through the polymer matrix is a very 
slow process, and it is assumed that the time scale of drug diffusion in the 
polymer matrix is much longer than the time scale of the experiment. 
5.2.2.1 Effects of dissolution on drug absorption 
Differences were observed in the dissolution properties of the nanoparticles. 
However, such differences in dissolution are not necessarily clinically relevant. 
Firstly, the concentration of drug used in the dissolution studies (0.02 mg/ml) is 
much lower than the concentration considered in the biopharmaceutical 
classification system. In BCS, for example, for a standard dose of 100 mg 
ketoprofen, the concentration in 250 ml of fluid is 0.4 mg/ml. For each composition 
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of nanoparticles, the limiting factor for drug absorption in the gastrointestinal tract 
was identified, assuming a standard dose of 100 mg of ketoprofen.  
Ketoprofen is a molecule having a high permeability [96, 262]. Therefore, it is 
almost completely absorbed in the gastrointestinal tract. For a drug molecule 
having a high permeability, the solubility can become the limiting factor for drug 
absorption. The classification of solubility depends on the dose of the drug. 
Considering a standard dose of 100 mg ketoprofen [263], ketoprofen can be 
classified as having a low solubility in acidic stomach fluid [96]. At pH 5, 
approximating the pH level of the intestine, a 100 mg dose of ketoprofen can be 
classified as having a high solubility [96]. Similarly, at pH 7.4, the approximate 
pH level of the colon, ketoprofen is highly soluble [96]. For pure ketoprofen, 
when the drug is in the gastrointestinal tract in a solution form, it is also 
absorbed as a result of its high permeability. Consequently, for pure ketoprofen 
of 100 mg dose, the gastric emptying time can be considered as the limiting step 
for drug absorption.  
Nanoparticles prepared from ketoprofen and the polymer Eudragit E can be 
regarded as an immediate release preparation. The nanoparticles dissolve in the 
acidic stomach fluid. However, all ketoprofen cannot be dissolved due to the fact 
the the total solubility of ketoprofen is lower than the amount of ketoprofen in a 
100 mg dose. Therefore, also for nanoparticles prepared from Eudragit E, the 
gastric emptying time is the limiting step for drug absorption. A pH-controlled 
preparation, consisting of ketoprofen and Eudragit L, is dissolved when the pH 
is higher than 5. Therefore, similarly to pure ketoprofen, for these nanoparticles 
the gastric emptying time is the limiting step for drug absorption. Neither drug 
nor the polymer is dissolved in the acidic stomach. Nanoparticles containing 
polymer Eudragit RS can also be denoted as a controlled-release preparation. In 
these nanoparticles, however, the polymer Eudragit RS controls the dissolution 
of ketoprofen from the particles at all pH levels. Therefore, for these 
nanoparticles, the product is the controlling factor for drug absorption. It can be 
concluded that only for this preparation, the nanoparticle formulation is likely to 
have an impact on drug absorption.  
The blood plasma levels of ketoprofen were modeled using a compartmental 
absorption and transit (CAT) model [264, 265]. The structure of the model 
having seven compartments in the intestine is shown in Figure 29. 
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Figure 29. Compartmental absorption and transit model [264]. 
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The model was tested both on literature data of ketoprofen [262, 266] and on 
nanoparticles of this study. Of the ketoprofen nanoparticles prepared, only the 
Eudragit RS nanoparticles could be modeled. To allow calculation of dissolution 
rate constant required in the model, the system studied should show first order 
dissolution kinetics. Eudragit E and Eudragit L nanoparticles prepared in this 
study do not show first order dissolution kinetics. The results of the modeling 
are shown in Figure 30. 
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Figure 30. CAT modeling (CAT predicted) of literature reference data 
(Observed) and CAT modeling (Nanoparticles predicted) of nanoparticles 
containing ketoprofen and Eudragit RS. 
From Figure 30, it can be seen that the modeling data fits the experimental data 
well. When Eudragit RS nanoparticles containing ketoprofen were modeled, the 
maximum blood plasma level of ketoprofen is observed in 120 minutes instead 
of 90 minutes of the modeled literature reference formulation. Therefore, it can 
be concluded that incorporating ketoprofen in Eudragit RS nanoparticles slightly 
affected the modeled time to peak plasma drug concentration, but the difference 
is small.  
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5.2.3 Drug release from nanoparticles containing beclomethasone 
dipropionate 
The drug release from nanoparticles containing 100% (w/w) beclomethasone 
dipropionate was analysed, and the results are shown in Figure 31. It can be 
observed that BDP nanoparticles dissolved faster than micronised BDP. Almost 
90% of drug amount is released from the nanoparticles in five minutes, whereas 
only 45% of drug amount is released at the same time from the micron-sized 
particles. However, in fifteen minutes, the released amount from the micron-
sized particles equals the amount released from the nanoparticles. Therefore, it 
can be concluded that the dissolution of drug from the nanoparticles was slightly 
faster than from the micron-sized particles, but the difference in the dissolution 
rates is very small.  
 
Figure 31. BDP release for pure BDP (particle size 90% less than 6 µm) and 
BDP nanoparticles.  
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5.2.4 Stability of the nanoparticles 
Physical stability of the nanoparticle dry powder was studied at three different 
conditions to evaluate the effects of temperature and relative humidity. The 
nanoparticles containing 33% (w/w) ketoprofen and 67% (w/w) Eudragit L were 
stored for three months in a refrigerator, at 25 °C at 0% relative humidity, and at 
25 °C at 75% relative humidity. It was observed that the particles did not show 
any changes in their morphology in the course of time, but remained spherical 
and smooth regardless of the storage conditions of the study. The nanoparticle 
powder as-prepared was amorphous, as peaks corresponding to diffraction from 
drug crystal lattice were not detected. After three months storage time, 
crystallinity was not detected in the XRD patterns (see Figure 32). Therefore, it 
was concluded that the nanoparticles are physically stable for at least a time 
period of three months. However, chemical stability was not analysed during this 
time period. The chemical purity during storage time should be evaluated using 
liquid chromatography to identify degradation products. 
 
Figure 32. X-ray diffraction patterns of nanoparticle dry powder containing 33% 
(w/w) ketoprofen and 67% (w/w) Eudragit L after 3 months storage time. A) 
Nanoparticle dry powder stored in a refrigerator. B) Nanoparticle dry powder 
stored at 25 °C at 0% relative humidity. C) Nanoparticle dry powder stored at 25 
°C at 75% relative humidity. The curves are shifted along y-axis for clarification. 
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6. Summary and conclusions 
Polymer nanoparticles were prepared using a novel method, namely, aerosol 
flow reactor method, and the properties of the nanoparticles were studied. The 
nanoparticles were prepared from various drugs and pharmaceutically acceptable 
methacrylic polymers. Such nanosized particles could be used, for example, for 
oral, ocular, or parenteral administration of drug materials. 
This method could be used to prepare spherical, amorphous, homogeneous 
matrix-type drug-polymer nanoparticles. The size distributions of the 
nanoparticles prepared were found to be unimodal and lognormal, reflecting the 
droplet size distribution produced by the atomiser. The concentration of the 
starting solution determined the resulting particle size.  
The morphology of the nanoparticles was affected by the solvent properties and 
the solvent composition. Particularly, the morphology of the particles was 
influenced by the solute solubility and the solvent vapour pressure. It was 
concluded that the polymeric component determined the morphology of the 
nanoparticles.  
The nanoparticles, when prepared, were amorphous, but depending on the 
thermal properties of the drug and on the interactions between the drug and the 
polymer, crystallisation of the drug could take place in collection. The 
nanoparticles containing beclomethasone dipropionate were found to be 
amorphous at room temperature regardless of the amounts of drug and polymer 
in the nanoparticles. Crystallisation of the amorphous beclomethasone 
dipropionate was observed when the nanoparticles were heated above glass 
transition temperatures of the drug and the polymer, provided that the amount of 
beclomethasone dipropionate was above the solubility limit of the drug in the 
polymer.  
In comparison, when the nanoparticles contained small drug molecules, such as 
ketoprofen and naproxen, it was found that the use of polymeric excipients was 
necessary to prevent crystallisation of the drugs at room temperature. For the 
nanoparticles prepared from a methacrylic acid - methyl methacrylate 
copolymer, the solubilities of drugs ketoprofen and naproxen in the 
nanoparticles were estimated to be 49.5% (w/w) and 24.1% (w/w), respectively. 
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A drug amount smaller than this remained in the amorphous solid solution 
structure of the nanoparticles, whereas a higher amount of drug crystallised. In 
general, for the nanoparticles prepared from ketoprofen and methacrylic 
polymers, a significant lowering in the glass transition temperature of the 
polymer was observed when ketoprofen amount was increased. 
As a conclusion it can be stated that, firstly, the interactions between the drug 
and the polymer determined the maximum amount of drug that could be 
solubilised in the amorphous polymer matrix. Large amounts of drug could be 
solubilised in the polymer, when the interactions between the drug and the 
polymer were strong. Below the solubility limit of the drug in the polymer, 
nanoparticles having amorphous solid solution structures were obtained. Above 
the solubility limit, the drug was observed to form crystallites, and amorphous 
nanoparticles could not be collected. Secondly, the crystallisation was dependent 
on the thermal properties of the materials. When the glass transition temperature 
of the drug was low, the drug had a tendency to crystallise already at room 
temperature. In comparison, when the drug had a high glass transition 
temperature, the crystallisation was observed to take place only when heat was 
applied to the nanoparticles.  
Further studies on extending this approach to other pharmaceutical materials are 
suggested. A wider range of both active drug molecules and polymer materials 
should be covered to see if the trends observed in this study apply also to other 
drug-polymer systems in a more general level. Stability studies of the 
amorphous particles at various conditions over long periods of time should give 
valuable insight on the feasibility of these nanoparticles. Furthermore, the 
incorporation of the nanoparticles into dosage forms, such as tablets or oral 
suspensions should be surveyed to allow further pharmaceutical product 
development. To increase the manufacturing and collection capacity 
considering, for example, scale-up issues, the particle collection should be 
modified. The collection device used in this study, Berner-type low pressure 
impactor, separates the particles according to their particle size onto 11 separate 
stages, which is not feasible and does not allow further scale-up. Adaptation of 
the collection to lower temperatures is likely to increase the stability of 
nanoparticles during collection, and warrants further studies. Chemical purity of 
the drugs as a function of preparation procedure temperature should be evaluated 
more closely, for example with chromatography. 
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